Item 1A. Risk Factors

An updated description of the risk factors associated with our business is set forth below. This description includes any material changes to and supersedes the description of the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2017. The risks and uncertainties discussed below are not the only ones facing our business. Please read the cautionary notice regarding forward-looking statements in Item 2 of Part 1I of this Quarterly Report on Form 10-Q under the heading ~~“Management’s~~"Management’s Discussion and Analysis of Financial Condition and Results of ~~Operations”.~~Operations."

Risk factors related to our overall business:

If we fail to adhere to all of the complex government laws and regulations that apply to our business, we could suffer severe consequences that could have a material adverse effect on our business, results of operations, financial condition and stock price.

Our operations are subject to extensive federal, state and local government laws and regulations, ~~including~~such as Medicare and Medicaid payment rules and regulations, federal and state anti-kickback laws, the Stark Law and analogous state self-referral prohibition statutes, the 21^st Century Cures Act, Federal Acquisition Regulations, the False Claims Act (FCA), the Civil Monetary Penalty statute, the Foreign Corrupt Practices Act (FCPA) and federal and state laws regarding the collection, use and disclosure of patient health information (e.g., Health Insurance Portability and Accountability Act of 1996 (HIPAA)) and the storage, handling, shipment, disposal and/or dispensing of pharmaceuticals and ~~administration of pharmaceuticals.~~blood products and other biological materials. The Medicare and Medicaid reimbursement rules impose complex and extensive requirements upon ~~dialysis~~healthcare providers as well. Moreover, the various laws and regulations that apply to our operations are often subject to varying interpretations and additional laws and regulations potentially affecting providers continue to be ~~promulgated. For example, on December 13, 2016, the 21~~^st ~~Century Cures Act was signed into law and, among other provisions, authorizes the Department of Health and Human Services (HHS) Office of Inspector General (OIG) to impose penalties on providers~~promulgated that engage in information blocking where there is knowledge that such practice is unreasonable and likely to interfere with, prevent, or materially discourage access, exchange, or use of electronic health information.may impact us. A violation or departure from any of these legal requirements may result in government audits, lower reimbursements, significant fines and penalties, the potential loss of certification, recoupment efforts or voluntary repayments, among other things.

We endeavor to comply with all legal requirements; however, there is no guarantee that we will be able to adhere to all of the complex government regulations that apply to our business. We further endeavor to structure all of our relationships with physicians and providers to comply with state and federal anti-kickback and physician self-referral laws. We utilize considerable resources to monitor laws and regulations and implement necessary changes. However, the laws and regulations in these areas are complex, changing and often subject to varying interpretations. For example, if an enforcement agency were to challenge the level of compensation that we pay our medical directors or the number of medical directors whom we engage, we could be required to change our practices, face criminal or civil penalties, pay substantial fines or otherwise experience a material adverse effect on our business, results of operations and financial condition as a result of a challenge to these arrangements.

In addition, failure to report and return overpayments within 60 days of when the overpayment ~~was~~is identified and quantified can lead to a violation of the FCA and associated penalties, as described in further detail below, and exclusion and penalties under the federal Civil Monetary Penalty statute, including civil monetary penalties of up to ~~$10,000~~$20,000 (adjusted for inflation) for each item or service for which a person received an identified overpayment and failed to report and return such overpayment. These obligations to report and return overpayments could subject our procedures for identifying and processing overpayments to greater scrutiny. We have made ~~significant~~ investments in resources to decrease the time it takes to identify, quantify and process overpayments, and we may be required to make additional investments in the future. From time to time we may conduct internal compliance reviews, the results of which may involve the identification of overpayments or other liabilities. In that regard, in the spring of 2015, we initiated an internal compliance review of our pharmacy business during which we identified potential billing and operational issues, including potential write-offs and discounts of patient co-payment obligations, and credits to payors for returns of prescriptions drugs, related to our pharmacy business. We have disclosed the results of this ongoing review to the government. An acceleration in our ability to identify and process overpayments could result in us refunding overpayments to government and other payors more rapidly than we have in the past which could have a material adverse effect on our operating cash flows. Overpayments subject us to refunds and related damages and potential liabilities.

Additionally, the federal government has used the FCA to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated against Medicare, Medicaid and ~~state~~other federally funded health care programs. Moreover, amendments to

the federal Anti-Kickback Statute in the 2010 Affordable Care Act (ACA) make claims tainted by anti-kickback violations potentially subject to liability under the FCA, including qui tam or whistleblower suits. The penalties for a violation of the FCA range from $5,500 to $11,000 (adjusted for inflation) for each false claim plus three times the amount of damages caused by each such claim which generally means the amount received directly or indirectly from the government. On ~~February 3, 2017,~~January 29, 2018, the Department of Justice (DOJ)

issued a final rule announcing adjustments to FCA penalties, under which the per claim penalty range increases to a range from ~~$10,957~~$11,181 to ~~$21,916~~$22,363 for penalties assessed after ~~February 3, 2017,~~January 29, 2018, so long as the underlying conduct occurred after November 2, 2015. Given the high volume of claims processed by our various operating units, the potential is high for substantial penalties in connection with any alleged FCA violations.

In addition to the provisions of the FCA, which provide for civil enforcement, the federal government can use several criminal statutes to prosecute persons who are alleged to have submitted false or fraudulent claims for payment to the federal government.

Certain civil investigative demands received by us or our subsidiaries specifically reference that they are in connection with FCA investigations alleging, among other things, that we or our subsidiaries presented or caused to be presented false claims for payment to the government. See ~~“Item 1. Legal Proceedings” in Part II of this report and~~ Note 10 to the condensed consolidated financial statements included in this report for further details.

We are subject to a Corporate Integrity Agreement (CIA) which, for our domestic dialysis business, requires us to report probable violations of criminal, civil or administrative laws applicable to any federal health care program for which penalties or exclusions may be authorized under applicable healthcare laws and regulations. See ~~“If~~"If we fail to comply with our Corporate Integrity Agreement, we could be subject to substantial penalties and exclusion from participation in federal healthcare programs that could have a material adverse effect on our business, results of operations and financial condition."

If any of our operations are found to violate these or other government laws or regulations, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and stock price, including:

Suspension or termination of our participation in government payment programs;

Refunds of amounts received in violation of law or applicable payment program requirements;

Loss of required government certifications or exclusion from government payment programs;

Loss of licenses required to operate healthcare facilities or administer pharmaceuticals in some of the states in which we operate;

Reductions in payment rates or coverage for dialysis and ancillary services and related pharmaceuticals;

Criminal or civil liability, fines, damages or monetary penalties for violations of healthcare fraud and abuse laws, including the federal Anti-Kickback Statute, Stark Law ~~violations,~~and FCA, or other failures to meet regulatory requirements;

Enforcement actions by governmental agencies and/or state claims for monetary damages by patients who believe their protected health information (PHI) has been used, disclosed or not properly safeguarded in violation of federal or state patient privacy laws, including HIPAA and the Privacy Act of 1974;

Mandated changes to our practices or procedures that significantly increase operating expenses;

Imposition of and compliance with corporate integrity agreements that could subject us to ongoing audits and reporting requirements as well as increased scrutiny of our billing and business practices which could lead to potential fines;

Termination of various relationships and/or contracts related to our business, including joint venture arrangements, medical director agreements, real estate leases and consulting agreements with ~~medical directors;~~physicians; and

Harm to our reputation which could impact our business relationships, affect our ability to obtain financing and decrease access to new business opportunities, among other things.

We are, and may in the future be, a party to various lawsuits, demands, claims, qui tam suits, governmental investigations and audits (including investigations or other actions resulting from our obligation to self-report suspected violations of law) and other legal ~~proceedings,~~matters, any of which could result in, among other things, substantial financial penalties or awards against us, substantial payments made by us, ~~harm to our reputation,~~ required changes to our business practices, exclusion from future participation in the Medicare, Medicaid and other federal healthcare programs and possible criminal penalties, any of which could have a material adverse effect on our business, results of operations and financial ~~condition.~~condition and materially harm our reputation.

We are the subject of a number of investigations and audits by the federal government. We have received subpoenas or other requests for documents from the federal government in connection with the Swoben private civil suit, the investigations underlying the two subpoenas regarding patient diagnosis coding received by DMG and its JSA subsidiary, the 2016 U.S.

~~Attorney Prescription Drug Investigation and the 2017 U.S. Attorney American Kidney Fund Investigation.~~governmental agencies. In addition, ~~to the foregoing inquiries and proceedings,~~ we are, ~~frequently~~and may in the future be, subject to other investigations and audits by state or federal ~~government~~governmental agencies and/or private civil qui tam complaints filed by relators and other lawsuits, demands, claims and legal ~~proceedings.~~proceedings, including investigations or other actions resulting from our obligation to self-report suspected violations of law.

Responding to subpoenas, investigations and other lawsuits, claims and legal proceedings as well as defending ourselves in such matters will continue to require management’s attention and cause us to incur significant legal expense. Negative findings or terms and conditions that we might agree to accept as part of a negotiated resolution of pending or future ~~government inquiries~~legal or ~~relator proceedings~~regulatory matters could result in, among other things, substantial financial penalties or awards against us, substantial payments made by us, harm to our reputation, required changes to our business practices, exclusion from future participation in the Medicare, Medicaid and other federal healthcare programs and, in certain cases, criminal penalties, any of which could have a material adverse effect on us. It is possible that criminal proceedings may be initiated against us and/or individuals in our business in connection with investigations by the federal government. ~~To our knowledge, no such proceedings have been initiated by the federal government against us at this time.~~ Other than as described in ~~“Item 1. Legal Proceedings” in Part II of this report and~~ Note 10 to the condensed consolidated financial statements included in this report, we cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which we are or may be subject from time to time, including those described in the aforementioned sections of this report, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on our business results of operations and financial condition. See ~~“Item 1. Legal Proceedings” in Part II of this report and~~ Note 10 to the condensed consolidated financial statements included in this report for further details regarding these and other matters.

Disruptions in federal government operations and funding create uncertainty in our industry and could have a material adverse effect on our business, results of operations and financial condition.

A substantial portion of our revenues is dependent on federal healthcare program reimbursement, and any disruptions in federal government operations could have a material adverse effect on our business, results of operations and financial condition. If the U.S. government defaults on its debt, there could be broad macroeconomic effects that could raise our cost of borrowing funds, and delay or prevent our future growth and expansion. Any future federal government shutdown, U.S. government default on its debt and/or failure of the U.S. government to enact annual appropriations could have a material adverse effect on our business, results of operations and financial condition. Additionally, disruptions in federal government operations may negatively impact regulatory approvals and guidance that are important to our operations, and create uncertainty about the pace of upcoming healthcare regulatory developments.

~~Healthcare reform~~Changes in federal and state health regulations could have a material adverse effect on our business, financial condition and results of operations.

We cannot predict how employers, private payors or persons buying insurance might react to the changes brought on by federal and state healthcare reform legislation, including the ACA and any subsequent legislation, or what form many of these regulations will take before implementation.

The ACA introduced healthcare insurance exchanges, which provide a marketplace for eligible individuals and small employers to purchase healthcare insurance. The business and regulatory environment continues to evolve as the exchanges mature, and statutes and regulations are challenged, changed and enforced. If commercial payor participation in the exchanges continues to decrease, it could have a material adverse effect on our business, results of operations and financial condition. Although we cannot predict the short- or long-term effects of ~~these factors,~~legislative or regulatory changes, we believe ~~the healthcare insurance exchanges~~that future market changes could result in ~~a reduction in ESRD patients covered by traditional commercial insurance policies and an increase in the number of patients covered through the exchanges under~~ more restrictive commercial plans with lower reimbursement rates or higher deductibles and co-payments that patients may not be able to pay. To the extent that ~~the ongoing implementation~~changes in statutes or regulations, or enforcement of ~~such~~statutes or regulations regarding the exchanges, or changes in ~~regulations or enforcement of regulations regarding the exchanges results~~other market conditions result in a reduction in reimbursement rates for our services from commercial and/or government payors, it could have a material adverse effect on our business, results of operations and financial condition.

The ACA also added several new tax provisions that, among other things, impose various fees and excise taxes, and limit compensation deductions for health insurance providers and their affiliates. These rules could negatively impact our cash flow

and tax liabilities. In addition, the ACA broadened the potential for penalties under the FCA for the knowing and improper retention of overpayments collected from government payors and reduced the timeline to file Medicare claims. As a result, we made significant investments in new resources to accelerate the time it takes us to identify, quantify and process overpayments and we deployed significant resources to reduce our timeline and improve our claims processing methods to ensure that our Medicare claims are filed in a timely fashion. However, we may be required to make additional investments in the future. Failure to timely identify, quantify and return overpayments may result in significant penalties, which could have a material adverse

effect on our business, results of operations and financial condition. Failure to file a claim within the one year window could result in payment denials, adversely affecting our business, results of operations and financial condition.

With the ACA, new models of care emerge and evolve and other initiatives in the government or private sector may arise, which could adversely impact our business. For example, the ~~CMS~~Centers for Medicare and Medicaid Services (CMS) Innovation Center (Innovation Center) is currently working with various healthcare providers to develop, refine and implement Accountable Care Organizations (ACOs) and other innovative models of care for Medicare and Medicaid beneficiaries, including Bundled Payments for Care Improvement Initiative, ~~CEC~~Comprehensive ESRD Care Model (CEC Model) (which includes the development of ~~ESRD~~end stage renal disease (ESRD) Seamless Care Organizations), ~~the Comprehensive Primary Care Initiative,~~ the Duals Demonstration, and other models. We are currently participating in the CEC Model with the Innovation Center, including with organizations in Arizona, Florida, and adjacent markets in New Jersey and Pennsylvania. Our U.S. dialysis business may choose to participate in additional models either as a partner with other providers or independently. Even in areas where we are not directly participating in these or other Innovation Center models, some of our patients may be assigned to an ACO, another ESRD Care Model, or another program, in which case the quality and cost of care that we furnish will be included in an ACO’s, another ESRD Care Model’s, or other program’s calculations. Additionally, CMS instituted new screening procedures, as required by the ACA, which we expect will delay the Medicare contractor approval process, potentially causing a delay in reimbursement. We anticipate the new screening and enrollment requirements will require additional personnel and financial resources and will potentially delay the enrollment and revalidation of our centers which in turn will delay payment. These delays could adversely affect our business, results of operations and financial condition. The Bipartisan Budget Act of 2018 (BBA) revised the manner in which beneficiaries are assigned to an ACO, specifically giving ACOs the choice to have beneficiaries assigned prospectively at the beginning of a performance year and giving beneficiaries the option to voluntarily align to the ACO in which the beneficiary’s main primary care provider participates. While prospective assignment may allow ACOs to identify beneficiaries for whom they will be held accountable and proactively take steps to ensure appropriate care, the ultimate impact of such changes on our business, results of operations and financial condition is not yet known.

Other ACA reform measures allow CMS to place a moratorium on new enrollment of providers and to suspend payment to providers upon a credible allegation of fraud from any source. These types of reform measures, as well as other measures, could adversely affect our business, results of operations, and financial condition, depending on the scope and breadth of the implementing regulations.

There is also a considerable amount of uncertainty as to the prospective implementation of the ACA and what similar measures or other changes might be enacted at the federal and/or state level. There have been multiple attempts through legislative action and legal challenges to repeal or amend the ACA. In addition, the 2016 Presidential and Congressional elections and subsequent developments in 2017 and 2018 have caused the future state of the exchanges and other ACA reforms to be unclear. While ~~it does appear likely that~~ there ~~will~~may be significant changes to the healthcare environment in the future, the specific changes and their timing are not yet apparent. As a result, there is considerable uncertainty ~~regarding~~surrounding the ~~future with respect to~~ ACA ~~reforms~~ including the exchanges, and, indeed, many core aspects of the current health care marketplace. Previously enacted reforms ~~as well as~~and future changes could have a material adverse effect on our business, financial condition and results of operations, including, for example, by limiting the scope of coverage or the number of patients who are able to obtain coverage through the exchanges and other health insurance programs, lowering or eliminating the cost-sharing reduction subsidies under the ACA, lowering our reimbursement rates, and/or increasing our expenses.

In ~~addition,~~August 2017, a proposition was submitted to be placed on the California ballot (Proposition 8) seeking to limit the amount of revenue a dialysis provider can earn on commercial patients taking into account only a portion of the costs incurred by a dialysis provider. Proposition 8 was submitted by, and is supported by, the Service Employees International Union - United Healthcare Workers West. Ballot initiatives similar to Proposition 8 have also been proposed in other states.

There has also been potential rule making and/or legislative efforts concerning charitable premium assistance. In December 2016, CMS published an interim final rule that questioned the use of charitable premium assistance for ESRD patients and would have established new ~~Conditions~~conditions for ~~Coverage~~coverage standards for dialysis facilities that would have required facilities that provide education to patients seeking individual market health plans to notify such patients of potential coverage options and educate them about the benefits of each option. The interim final rule would have required facilities to ensure that insurers are informed of and have agreed to accept charitable assistance from a third party.facilities. In January 2017, a federal district court in Texas issued a preliminary injunction on CMS’ interim final rule and in June 2017, at the request of CMS, the court stayed the proceedings while CMS ~~conducts~~pursues new rulemaking ~~proceedings.~~options. In November 2017, when CMS published the 2018 final rule that updates payment policies and rates under the ESRD Prospective Payment System (PPS), and the 2019 proposed

Notice of Benefit and Payment Parameters, it did not pursue further discussion or rule making related to charitable premium assistance or propose changes to historical charitable premium assistance guidelines. This does not preclude CMS or another regulatory agency or legislative authority from issuing a new rule or guidance that challenges charitable premium assistance.

During the first quarter of 2018, a bill was introduced in the California legislature related to charitable premium assistance, SB 1156. An amended version of the bill is proceeding to the Assembly appropriations committee and ~~any other~~then Assembly floor. If passed and signed into law in its current form, SB 1156 would impose restrictions and obligations related to the use by patients on commercial plans of charitable premium assistance in the state of California and would limit the amounts paid to a provider for services provided to those patients, if that provider has a financial relationship with the organization providing charitable premium assistance.

Any law, rule, or guidance proposed or issued by CMS or other federal or state regulatory or legislative authorities, ~~limiting~~including the pending ballot initiative and bill in California, described above, restricting or prohibiting the ability of patients with access to alternative coverage from selecting a marketplace plan on or off exchange, limiting the payments that a dialysis provider can receive for treatments provided to commercial patients, affecting payments made to providers for services provided to patients who receive charitable premium assistance and/or otherwise ~~limiting~~restricting or prohibiting the use of charitable premium assistance, could cause us to incur substantial costs to challenge any such proposed measures, impact our dialysis center development plans, and if passed and/or implemented, could adversely impact dialysis centers across the U.S. making certain centers economically unviable, lead to the closure of certain centers, restrict the ability of dialysis patients to obtain and maintain optimal insurance coverage, and have a material adverse effect on our business, results of operations, and financial condition.

~~Federal and state privacy~~Privacy and information security laws are complex, and if we fail to comply with applicable laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information on our behalf, or if we fail to properly maintain the integrity of our data, protect our proprietary rights to our systems or defend against cybersecurity attacks, we may be subject to government or private actions due to privacy and security breaches, any of which could have a material adverse effect on our business, financial condition and results of operations or materially harm our reputation.

We must comply with numerous federal and state laws and regulations in both the U.S. and the foreign jurisdictions in which we operate governing the collection, dissemination, access, use, security and privacy of PHI, including HIPAA and its implementing privacy, security, and related regulations, as amended by the federal Health Information Technology for Economic and Clinical Health Act (HITECH) and collectively referred to as HIPAA. We are also required to report known breaches of PHI consistent with applicable breach reporting requirements set forth in applicable laws and regulations. From time to time, we may be subject to both federal and state inquiries or audits related to HIPAA, HITECH and related state laws associated with complaints, desk audits, and self-reported breaches. If we fail to comply with applicable privacy and security laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information, including PHI, on our behalf, properly maintain the

integrity of our data, protect our proprietary rights, ~~to our systems,~~ or defend against cybersecurity attacks, it could materially harm our reputation or have a material adverse effect on our business, results of operations and financial condition. ~~As set forth in applicable laws and regulations, we are required to report known privacy breaches~~These risks may be intensified to the ~~Office~~extent that we increase our use of ~~Civil Rights (OCR)~~third-party service providers that utilize sensitive personal information, including PHI, on our behalf.

Data protection laws are evolving globally, and may add additional compliance costs and legal risks to our international operations. In Europe, the General Data Protection Regulation (GDPR) became effective on May 25, 2018. The GDPR applies to entities that are established in the European Union (EU), as well as extends the scope of EU data protection laws to foreign companies processing data of individuals in the EU. The GDPR imposes a comprehensive data protection regime with penalties of up to the greater of 4% of worldwide turnover or €20 million. The costs of compliance with, and other burdens imposed by, the GDPR and other new laws, regulations and policies implementing the GDPR may impact our European operations and/or limit the ~~appropriate~~ways in which we can provide services or use personal data collected while providing services.

Data protection laws are also evolving nationally, and may add additional compliance costs and legal risks to our US operations. The California legislature recently passed the California Consumer Protection Act (CCPA), which is scheduled to become effective January 1, 2020. The CCPA is a privacy bill that requires certain companies doing business in California to disclose information regarding the collection and use of a consumer’s personal data and to delete a consumer’s data upon request. The Act also permits the imposition of civil penalties and expands existing state ~~regulatory bodies. From time to time, we are~~security laws by providing a private right of action for consumers in certain circumstances where consumer data is subject to ~~both federal~~a breach. The Company is still evaluating whether and ~~state inquiries related to HIPAA, HITECH~~how this rule will impact our US operations and ~~related state laws associated with complaints, desk audits, and self-reported breaches.~~

/or limit the ways in which we can provide services or use personal data collected while providing services. Information security risks have significantly increased in recent years in part because of the proliferation of new technologies, the use of the Internet and telecommunications technologies to conduct

our operations, and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign state agents. Our business and operations rely on the secure processing, transmission and storage of confidential, proprietary and other information in our computer systems and ~~networks.~~networks, including sensitive personal information, including PHI, social security numbers, and credit card information of our patients, teammates, physicians, business partners and others.

We are continuously implementing multiple layers of security measures through technology, processes, and our people. We utilize ~~current~~ security technologies to protect and maintain the integrity of our information systems and data and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, our facilities and systems and those of our third-party service providers may be vulnerable to privacy and security incidents; security attacks and breaches; acts of vandalism or theft; computer viruses and other malicious code; coordinated attacks by a variety of actors, including activist ~~entities;~~entities or state sponsored cyberattacks; emerging cybersecurity risks; cyber risk related to connected devices; misplaced or lost data; programming and/or human errors; or other similar events that could impact the security, reliability, and availability of our systems. Internal or external parties may attempt to circumvent our security systems, and we have in the past, and expect that we will in the future, experience external attacks on our network including reconnaissance probes, denial of service attempts, malicious software attacks including ransomware or other attacks intended to render our internal operating systems or data unavailable, and phishing attacks or business email compromise. Cybersecurity requires ongoing investment and diligence against evolving threats. Emerging and advanced security threats, including coordinated attacks, require additional layers of security which may disrupt or impact efficiency of operations. ~~Cybersecurity requires ongoing investment~~As with any security program, there always exists the risk that employees will violate our policies despite our compliance efforts or that certain attacks may be beyond the ability of our security and other systems to detect. There can be no assurance that investments and diligence ~~against evolving threats.~~will be sufficient to prevent or timely discover an attack.

Any security breach involving the misappropriation, loss or other unauthorized disclosure or use of confidential information, including PHI, financial data, competitively sensitive information, or other proprietary data, whether by us or a third party, could have a material adverse effect on our business, financial condition, and results of operations and materially harm our reputation. We may be required to expend significant additional resources to modify our protective measures, to investigate and remediate vulnerabilities or other exposures, or to make required notifications. The occurrence of any of these events could, among other things, result in interruptions, delays, the loss or corruption of data, cessations in the availability of systems and liability under privacy and security laws, all of which could have a material adverse effect on our business, financial condition or results of operations, materially harm our reputation and trigger regulatory actions and private party litigation. If we are unable to protect the physical and electronic security and privacy of our databases and transactions, we could be subject to potential liability and regulatory action, our reputation and relationships with our patients and vendors would be harmed, and our business, results of operations and financial condition could be materially and adversely affected. Failure to adequately protect and maintain the integrity of our information systems (including our networks) and data, or to defend against cybersecurity attacks, could subject us to monetary fines, civil suits, civil penalties or criminal sanctions and requirements to disclose the breach publicly, and could further result in a material adverse effect on our business, results of operations and financial condition or harm our reputation. As malicious cyber activity escalates, including activity that originates outside of the United States, the risks we face relating to transmission of data and our use of service providers outside of our network, as well as the storing or processing of data within our network, intensify. There have been increased international, federal and state ~~HIPAA~~ and other privacy, data protection and security enforcement efforts and we expect this trend to continue. While we maintain cyber liability insurance, this insurance may not cover us for all types of losses and may not be sufficient to protect us against the amount of all losses.

We may engage in acquisitions, mergers, joint ventures or dispositions, which may affect our results of operations, debt-to-capital ratio, capital expenditures or other aspects of our business, and if businesses we acquire have liabilities we are not aware of, we could suffer severe consequences that would have a material adverse effect on our business, results of operations and financial condition.

Our business strategy includes growth through acquisitions of dialysis centers and other businesses, as well as entry into joint ventures. We may engage in acquisitions, mergers, joint ventures or dispositions or expand into new business models, which may affect our results of operations, debt-to-capital ratio, capital expenditures or other aspects of our business. There can be no assurance that we will be able to identify suitable acquisition targets or merger partners or buyers for dispositions or that, if identified, we will be able to ~~acquire these targets on acceptable terms or~~ agree to terms with merger ~~partners.~~partners, acquire these targets or make these dispositions on acceptable terms or on the desired timetable. There can also be no assurance that we will be successful in completing any acquisitions, mergers or dispositions that we announce, executing new business models or integrating any acquired business into our overall operations. There is no guarantee that we will be able to operate acquired businesses successfully as stand-alone businesses, or that any such acquired business will operate profitably or will not otherwise have a material adverse effect on our business, results of operations and financial condition. Further, we cannot be certain that key talented individuals at the business

being acquired will continue to work for us after the acquisition or that they will be able to continue to successfully manage or have adequate resources to successfully operate any acquired business.

In addition, certain of our newly and previously acquired dialysis centers and facilities have been in service for many years, which may result in a higher level of maintenance costs. Further, our facilities, equipment and information technology may need to be improved or renovated to maintain or increase operational efficiency, compete for patients and medical directors, or meet changing regulatory requirements. Increases in maintenance costs and capital expenditures could have a material adverse effect on our financial condition, results of operations and cash flows.

Businesses we acquire may have unknown or contingent liabilities or liabilities that are in excess of the amounts that we originally estimated, and may have other issues, including those related to internal controls over financial reporting or issues that could affect our ability to comply with healthcare laws and regulations and other laws applicable to our expanded business. As a result, we cannot make any assurances that the acquisitions we consummate will be successful. Although we generally seek indemnification from the sellers of businesses we acquire for matters that are not properly disclosed to us, we are not always successful. In addition, even in cases where we are able to obtain indemnification, we may discover liabilities greater than the contractual limits, the amounts held in escrow for our benefit (if any), or the financial resources of the indemnifying party. In the event that we are responsible for liabilities substantially in excess of any amounts recovered through rights to indemnification or alternative remedies that might be available to us, or any applicable insurance, we could suffer severe consequences that could have a material adverse effect on our business, results of operations and financial condition.

Additionally, joint ventures, including our Asia Pacific ~~Joint Venture (APAC JV),~~joint venture, and minority investments inherently involve a lesser degree of control over business operations, thereby potentially increasing the financial, legal, operational and/or compliance risks associated with the joint venture or minority investment. In addition, we may be dependent on joint venture partners, controlling shareholders or management who may have business interests, strategies or goals that are inconsistent with ours. Business decisions or other actions or omissions of the joint venture partner, controlling shareholders or management may adversely affect the value of our investment, result in litigation or regulatory action against us, result in reputational harm to us or adversely affect the value of our investment or partnership. There can be no assurances that these joint ventures and/or minority investments ultimately will be successful.

If we are ~~not able~~unable to ~~continue to make acquisitions,~~ compete successfully, including implementing our growth strategy and/or ~~maintain an acceptable level of non-acquired growth, or if we face significant patient attrition to~~retaining our ~~competitors or a reduction in the number of our medical directors or associated~~ physicians and patients, it could materially adversely affect our business, results of operations and financial condition.

Acquisitions, patient retention and medical director and physician retention are an important ~~part~~parts of our growth strategy. We face intense competition from other companies for acquisition targets. In our U.S. dialysis business, we continue to face increased competition from large and medium-sized providers, among others, which compete directly with us for the limited acquisition targets as well as for individual patients and medical directors. In addition, we compete for individual patients, physicians and medical directors based in part on the quality of our facilities. Moreover, as we continue our international ~~dialysis~~ expansion into various international markets, we will continue to face competition from large and medium-sized providers for these acquisition targets as well. As we and our competitors continue to grow and open new dialysis centers, each center in the United States is required by applicable regulations to have a medical director, and we may not be able to retain an adequate number of nephrologists to serve as medical directors. Because of the ease of entry into the dialysis business and the ability of physicians to be medical directors for their own centers, competition ~~for growth~~ in existing and expanding markets is not limited to large competitors with substantial financial resources. Individual nephrologists have opened their own dialysis units or facilities. There also has been increasing indications of interest from non-traditional dialysis providers and others to enter the dialysis space and develop innovative technologies or business activities that could be disruptive to the industry. Although these potential new competitors and others may face operational and/or financial challenges, if their efforts to offer dialysis services or develop innovative technology or business activities in the dialysis or pre-dialysis space are successful and we are unable to effectively compete, it could materially negatively impact our business. In addition, Fresenius USA, our largest competitor, manufactures a full line of dialysis supplies and equipment in addition to owning and operating dialysis centers. This may give it cost advantages over us because of its ability to manufacture its own ~~products. If we are not able to continue to make acquisitions, continue to maintain acceptable levels of non-acquired growth,~~products or ~~if we face significant patient attrition to~~prevent us from accessing existing or new technology on a cost-effective basis. See further discussion regarding risks associated with our ~~competitors or if a physician chooses not to refer to DaVita, it could adversely affect our business, results of operations and financial condition.~~

~~Our ability to effectively provide~~suppliers under the ~~services we offer could be negatively impacted if~~heading below, “If certain of our suppliers do not meet our needs, if there are material price increases, if we are not reimbursed or adequately reimbursed for drugs we purchase or if we are unable to effectively access new technology ~~which~~or superior products, it could negatively impact our ability to effectively provide the services we offer and could have a material adverse effect on our business, results of operations and financial condition.” If we are not able to effectively implement our growth strategy, including by making acquisitions at the desired pace or at all; continue to maintain the expected or desired level of non-acquired growth; if we face significant patient attrition to our competitors or as a result of new business activities, new technology or reduced prevalence of ESRD or other reductions in demand for dialysis treatments that we offer; or if physicians choose not to refer to our clinics, it could materially adversely affect our business, results of operations and financial condition.

If certain of our suppliers do not meet our needs, if there are material price increases, if we are not reimbursed or adequately reimbursed for drugs we purchase or if we are unable to effectively access new technology or superior products, it could negatively impact our ability to effectively provide the services we offer and could have a material adverse effect on our business, results of operations and financial condition.

We have significant suppliers that ~~are either~~may be the sole or primary source of products critical to the services we provide, ~~including Amgen, Baxter, Fresenius USA, NxStage Medical, Inc. and others~~ or to which we have committed obligations to make ~~purchases.~~purchases, sometimes at particular prices. If any of these suppliers do not meet our needs for the products they supply, including in the event of a product recall, shortage or dispute, and we are not able to find adequate alternative sources, if we experience material price increases from these suppliers that we are unable to mitigate, or if some of the drugs that we purchase are not reimbursed or not adequately reimbursed by commercial or government payors, ~~or through the bundled payment rate by Medicare,~~it could have a material adverse impact on our business, results of operations and financial ~~condition could be materially reduced.~~condition. In addition, the technology related to the products critical to the services we provide is subject to new developments which may result in superior products. If we are not able to access superior products on a cost-effective basis or if suppliers are not able to fulfill our requirements for such products, we could face patient attrition and other negative consequences which could have a material adverse effect on our business, results of operations and financial condition.

DMG operates in a different line of business from our historical business, and we face challenges managing DMG and may not realize anticipated benefits.

~~DMG~~DaVita Medical Group (DMG) operates in a different line of business from our historical business. We may not have the expertise, experience and resources to pursue all of our businesses at once, and we may be unable to successfully operate all businesses in the combined company. The administration of DMG requires implementation of appropriate operations, management, forecasting, and financial reporting systems and controls. We ~~experience~~have experienced difficulties in effectively implementing these and other systems. The management of

DMG requires and will continue to require the focused attention of our management team, including a significant commitment of its time and resources. The need for management to focus on these matters could have a material adverse effect on our business, results of operations and financial condition. If the DMG operations ~~are~~continue to be less profitable than we currently anticipate or we do not have the experience, the appropriate expertise or the resources to pursue all businesses in the combined company, our results of operations and financial condition may be materially and adversely ~~affected, and in~~affected. In that regard, we have taken goodwill impairment charges of ~~$492 million~~$1.093 billion in total and may continue incurring additional impairment charges.

Laws regulating the corporate practice of medicine could restrict the manner in which DMG and other subsidiaries of ours are permitted to conduct their respective business, and the failure to comply with such laws could subject these entities to penalties or require a restructuring of these ~~businesses~~businesses.

Some states have laws that prohibit business entities, such as DMG and other subsidiaries of ours, including but not limited to, Nephrology Practice Solutions, ~~Paladina Health,~~ DaVita Health Solutions, VillageHealth, and Lifeline, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians (also known collectively as the corporate practice of medicine) or engaging in certain arrangements, such as fee-splitting, with physicians. In some states these prohibitions are expressly stated in a statute or regulation, while in other states the prohibition is a matter of judicial or regulatory interpretation. Of the states in which DMG currently operates, California, Colorado, Nevada and Washington generally prohibit the corporate practice of medicine, and other states may as well.

~~In California, Colorado, Nevada~~DMG and ~~Washington, DMG operates~~other DaVita entities operate by maintaining long-term contracts with ~~its~~their associated physician groups which are each owned and operated by physicians and which employ or contract with additional physicians to provide physician services. Under these arrangements, DMG ~~provides~~and such other DaVita entities provide non-medical management services and ~~receives~~receive a management fee for providing ~~non-medical management~~these services; however, DMG ~~does~~and such other DaVita entities do not represent that ~~it offers~~they offer medical services, and ~~does~~do not exercise influence or control over the practice of medicine by the physicians or the associated physician groups.

In addition to the above management arrangements, DMG has certain contractual rights relating to the orderly transfer of equity interests in certain of its ~~associated California, Colorado, Nevada and Washington~~ physician groups through succession agreements and other arrangements with their physician equity holders. However, such equity interests cannot be transferred to or held by DMG or by any non-professional organization. Accordingly, neither DMG nor DMG’s subsidiaries directly own any equity interests in any physician groups in California, Colorado, Nevada and Washington. The other DaVita entities operating in these and multiple other states have similar agreements and arrangements. In the event that any of these associated physician groups fail to comply with the management arrangement or any management arrangement is terminated and/or DMG or any of the other DaVita entities is unable to enforce its contractual rights over the orderly transfer of equity interests in its associated physician groups, such

events could have a material adverse effect on ~~DMG’s~~the business, results of operations and financial ~~condition.~~condition of DMG and such other DaVita entities.

It is possible that a state regulatory agency or a court could determine that DMG’s agreements with physician equity holders of certain managed California, Colorado, Nevada and Washington associated physician groups and the way DMG carries out these arrangements as described above, either independently or coupled with the management services agreements with such associated physician groups, are in violation of the corporate practice of medicine doctrine. As a result, these arrangements could be deemed invalid, potentially resulting in a loss of revenues and an adverse effect on results of operations derived from such associated physician groups. Such a determination could force a restructuring of DMG’s management arrangements with associated physician groups in California, Colorado, Nevada and/or Washington, which might include revisions of the management services agreements, including a modification of the management fee and/or establishing an alternative structure that would permit DMG to contract with a physician network without violating the corporate practice of medicine prohibition. There can be no assurance that such a restructuring would be feasible, or that it could be accomplished within a reasonable time frame without a material adverse effect on DMG’s business, results of operations and financial condition. These same risks exist for the other DaVita entities utilizing similar structures.

In December 2013, ~~DHPC~~DaVita Health Plan of California, Inc. (DHPC) obtained a restricted Knox-Keene license in California, which permits DHPC to contract with health plans in California to accept global risk without violating the corporate practice of medicine prohibition. However, DMG and DMG’s Colorado, Nevada and Washington associated physician groups, as well as those physician equity holders of associated physician groups who are subject to succession agreements with DMG, could be subject to criminal or civil penalties or an injunction for practicing medicine without a license or aiding and abetting the unlicensed practice of medicine.

The level of our current and future debt could have an adverse impact on our business and our ability to generate cash to service our indebtedness and for other intended purposes depends on many factors beyond our control.

We have substantial debt outstanding, we recently incurred a substantial amount of additional debt in connection with our entry into the ~~DMG transaction~~Increase Joinder Agreement, and we may continue to incur additional indebtedness in the future. For additional details regarding specific risks we face regarding the sale of DMG, see the discussion in the risk factors under the heading "Risk factors related to the sale of DMG." Our inability to generate sufficient cash to service our substantial indebtedness and for other intended purposes could have important consequences to you, for example, it could:

make it difficult for us to make payments on our debt securities;

increase our vulnerability to general adverse economic and industry conditions;

require us to dedicate a substantial portion of our cash ~~flow~~flows from operations to payments on our indebtedness, thereby reducing the availability of our cash flow to fund working capital, capital expenditures, acquisitions and investments, repurchases of stock at the levels intended or announced, or at all, and other general corporate purposes;

limit our flexibility in planning for, or reacting to, changes in our business and the markets in which we operate;

expose us to interest rate volatility that could adversely affect our business, results of operations and financial condition, and our ability to service our indebtedness;

place us at a competitive disadvantage compared to our competitors that have less debt; and

limit our ability to borrow additional ~~funds.~~funds, or to refinance existing debt on favorable terms when otherwise available.

In addition, we may continue to incur ~~substantial~~ additional indebtedness in the ~~future. The terms~~future, and the amount of that additional indebtedness may be substantial. Although the indentures governing our senior notes and the agreement governing our senior secured credit facilities ~~will allow us~~include covenants that could limit our indebtedness, we currently have the ability to incur substantial additional debt. IfThe related risks described above could intensify, in particular, if there is a delay in closing the sale of DMG or the sale of DMG does not close, or if new debt is added to current debt ~~levels, the related risks described above could intensify.~~levels.

Our ability to make payments on our indebtedness, ~~and~~ to fund planned capital expenditures and expansion efforts, including any strategic acquisitions we may make in the future, to repurchase our stock at the levels intended or announced and to meet

our other liquidity needs, will depend on our ability to generate cash. This, to a certain extent, is subject to general economic, financial, competitive, regulatory and other factors that are beyond our control.

After the pending sale of DMG closes, our cash flows will be reduced accordingly. We cannot provide ~~assurance~~assurances that our business will generate sufficient cash ~~flow~~flows from operations in the future or that future borrowings will be available to us in an amount sufficient to enable us to service our indebtedness or to fund other liquidity ~~needs.~~needs, including those described above. If we are unable to generate sufficient funds to service our outstanding indebtedness or to meet our other liquidity needs, including the intended purposes described above, we may be required to refinance, restructure, or otherwise amend some or all of such obligations, sell assets, change our intended or announced uses or strategy for capital deployment, including for stock repurchases, reduce capital expenditures or planned expansions or raise additional cash through the sale of our equity. We cannot make any assurances that ~~we would be able to obtain~~any such refinancing, ~~on terms as favorable as our existing financing terms or that such restructuring activities,~~restructurings, sales of assets, or issuances of equity can be accomplished or, if accomplished, can be accomplished on favorable terms or that if accomplished that they would raise sufficient funds to meet these ~~obligations.~~obligations or our other liquidity needs.

The borrowings under our senior secured credit facilities are guaranteed by a substantial portion of our direct and indirect ~~wholly-owned~~wholly owned domestic subsidiaries, including certain of DMG’s subsidiaries, and are secured by a substantial portion of our and our subsidiaries’ ~~assets.~~assets, including those of certain of DMG’s subsidiaries. After the sale of DMG closes, we will have fewer assets with which to secure future debt or refinance or restructure existing debt. This will likely reduce the total amount of secured debt that we will be able to incur and may increase the interest rate we are required to pay on our existing secured debt and any secured debt we issue in the future. In addition, by reducing the amount of assets available to meet the claims of our secured creditors, it may also adversely affect the interest rates on our existing unsecured debt and any unsecured debt we issue in the future.

We may be subject to liability claims for damages and other expenses that are not covered by insurance or exceed our existing insurance coverage that could have a material adverse effect on our business, results of operations, financial condition and ~~financial condition.~~reputation.

Our operations and how we manage our Company may subject us, as well as our officers and directors to whom we owe certain defense and indemnity obligations, to litigation and liability for damages. Our business, profitability and growth prospects could suffer if we face negative publicity or we pay damages or defense costs in connection with a claim that is outside the scope or limits of coverage of any applicable insurance coverage, including claims related to adverse patient events, contractual disputes, professional and general liability and directors’ and officers’ duties. In addition, we have received ~~several~~ notices of claims from commercial payors and other third parties, as well as subpoenas and CIDs from the federal government, related to our business practices, including our historical billing practices and the historical billing practices of acquired businesses. Although the ultimate outcome of these claims cannot be predicted, an adverse result with respect to one or more of these claims could have a material adverse effect on our business, results of operations and financial condition. We ~~currently~~ maintain insurance coverage for those risks we deem are appropriate to insure against and make determinations about whether to self-insure as to other risks or layers of coverage. However, a successful claim, including a professional liability, malpractice or negligence claim which is in excess of any applicable insurance coverage, or that is subject to our self-insurance retentions, could have a material adverse effect on our business, results of operations, financial condition and ~~financial condition.~~reputation. Additionally, as a result of the broad scope of our DMG division’s medical practice, we are exposed to medical malpractice claims, as well as claims for damages and other expenses, that may not be covered by insurance or for which adequate limits of insurance coverage may not be available.

In addition, if our costs of insurance and claims increase, then our earnings could decline. Market rates for insurance premiums and deductibles have been steadily increasing. Our business, results of operations and financial condition could be materially and adversely affected by any of the following:

the collapse or insolvency of our insurance carriers;

further increases in premiums and deductibles;

increases in the number of liability claims against us or the cost of settling or trying cases related to those claims; or

an inability to obtain one or more types of insurance on acceptable terms, if at all.

If we fail to successfully maintain an effective internal control over financial reporting, the integrity of our financial reporting could be compromised, which could have a material adverse effect on our ability to accurately report our financial results and the market’s perception of our business and our stock price.

The integration of acquisitions and addition of new business lines into our internal control over financial reporting has required and will continue to require significant time and resources from our management and other personnel and has increased, and will continue to, increase our compliance costs. Failure to maintain an effective internal control environment could have a material adverse effect on our ability to accurately report our financial results and the market’s perception of our business and our stock price. In addition, we could be required to restate our financial results in the event of a significant failure of our internal control over financial reporting or in the event of inappropriate application of accounting principles.

Deterioration in economic conditions and further disruptions in the financial markets could have a material adverse effect on our business, results of operations and financial condition.

Deterioration in economic conditions could have a material adverse effect on our business, results of operations and financial condition. Among other things, the potential decline in federal and state revenues that may result from such conditions may create additional pressures to contain or reduce reimbursements for our services from Medicare, Medicaid and other government sponsored programs. Increases in job losses in the U.S. as a result of adverse economic conditions has and may continue to result in a smaller percentage of our patients being covered by an employer group health plan and a larger percentage being covered by lower paying Medicare and Medicaid programs. Employers may also select more restrictive commercial plans with lower reimbursement rates. To the extent that payors are negatively impacted by a decline in the economy, we may experience further pressure on commercial rates, a further slowdown in collections and a reduction in the amounts we expect to collect. In addition, uncertainty in the financial markets could adversely affect the variable interest rates payable under our credit facilities or could make it more difficult to obtain or renew such facilities or to obtain other forms of financing in the future, if at all. Any or all of these factors, as well as other consequences of a deterioration in economic conditions which cannot currently be anticipated, could have a material adverse effect on our business, results of operations and financial condition.

We could be subject to adverse changes in tax laws, regulations and interpretations or challenges to our tax positions.

We are subject to tax laws and regulations of the U.S. federal, state and local governments as well as various foreign jurisdictions. We compute our income tax provision based on enacted tax rates in the jurisdictions in which we operate. As the tax rates vary among jurisdictions, a change in earnings attributable to the various jurisdictions in which we operate could result in an unfavorable change in our overall tax provision.

From time to time, changes in tax laws or regulations may be proposed or enacted that could adversely affect our overall tax liability. For example, the recent U.S. tax legislation enacted on December 22, 2017, represents a significant overhaul of the U.S. federal tax code. This tax legislation significantly reduced the U.S. statutory corporate tax rate and made other changes that have and will reduce our effective U.S. federal tax rate in current and future periods. However, the tax legislation also included a number of provisions, including, but not limited to, the limitation or elimination of various deductions or credits (including for interest expense and for performance-based compensation under Section 162(m)), the imposition of taxes on certain cross-border payments or transfers, the changing of the timing of the recognition of certain income and deductions or their character, and the limitation of asset basis under certain circumstances, any of which could significantly and adversely affect our U.S. federal income tax position. The legislation also made significant changes to the tax rules applicable to insurance companies and other entities with which we do business. The estimated impact of the new law is based on management’s current knowledge and assumptions. We are continuing to evaluate the overall impact of this tax legislation on our operations and U.S. federal and state income tax position. The actual impact of the new law could be materially different from our current estimates based on our actual results, or our further analysis of the new law or any guidance and regulations that may be issued in the future. There can be no assurance that changes in tax laws or regulations, both within the U.S. and the other jurisdictions in which we operate, will not materially and adversely affect our effective tax rate, tax payments, financial condition and results of operations. Similarly, changes in tax laws and regulations that impact our patients, business partners and counterparties or the economy generally may also impact our financial condition and results of operations.

In addition, tax laws and regulations are complex and subject to varying interpretations, and any significant failure to comply with applicable tax laws and regulations in all relevant jurisdictions could give rise to substantial penalties and liabilities. We are regularly subject to audits by tax authorities and, although we believe our tax estimates are appropriate, the final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals. Any changes in enacted tax laws (such as the recent U.S. tax legislation), rules or regulatory or judicial interpretations; any adverse outcome in connection with tax audits in any jurisdiction; or any change in the pronouncements

relating to accounting for income taxes could materially and adversely impact our effective tax rate, tax payments, financial condition and results of operations.

Expansion of our operations to and offering our services in markets outside of the U.S. subjects us to political, economic, legal, operational and other risks that could have a material adverse effect on our business, results of operations and financial condition.

We are continuing to expand our operations by offering our services and entering new lines of business in certain markets outside of the U.S., which increases our exposure to the inherent risks of doing business in international markets. Depending on the market, these risks include those relating to:

changes in the local economic environment;

political instability, armed conflicts or terrorism;

social changes;

intellectual property legal protections and remedies;

trade regulations;

procedures and actions affecting approval, production, pricing, reimbursement and marketing of products and services;

foreign currency;

repatriating or moving to other countries cash generated or held abroad, including considerations relating to tax-efficiencies and changes in tax laws;

export controls;

lack of reliable legal systems which may affect our ability to enforce contractual rights;

changes in local laws or regulations;

potentially longer ramp-up times for starting up new operations and for payment and collection cycles;

financial and operational, and information technology systems integration; ~~and~~

failure to comply with U.S. laws, such as the FCPA, or local laws that prohibit us, our partners, or our partners’ or our intermediaries from making improper payments to foreign officials for the purpose of obtaining or retaining ~~business.~~business; and

data and privacy restrictions.

Issues relating to the failure to comply with ~~any of the above~~applicable non-U.S. laws, requirements or restrictions may also impact our domestic business and/or raise scrutiny on our domestic practices.

Additionally, some factors that will be critical to the success of our international business and operations will be different than those affecting our domestic business and operations. For example, conducting international operations requires us to devote significant management resources to implement our controls and systems in new markets, to comply with local laws and regulations and to overcome the numerous new challenges inherent in managing international operations, including those based on differing languages, cultures and regulatory environments, and those related to the timely hiring, integration and retention of a sufficient number of skilled personnel to carry out operations in an environment with which we are not familiar.

~~We anticipate expanding~~Any expansion of our international operations through acquisitions ~~of varying sizes~~ or through organic growth ~~which~~ could increase these risks. Additionally, ~~though~~while we ~~might~~may invest material amounts of capital and incur significant costs in connection with the growth and development of our international operations, ~~there is no assurance that~~including to start up or acquire new operations, we ~~will~~may not be able to operate them profitably ~~anytime soon, if~~on the anticipated timeline, or at all. As

These risks could have a ~~result, we would expect these costs~~material adverse effect on our business, results of operations and financial condition.

Risk factors related to the sale of DMG:

The announcement and pendency of the sale of DMG may adversely affect our business, results of operations and financial condition.

The announcement and pending sale of DMG may be ~~dilutive~~disruptive to our ~~earnings~~business and may adversely affect our relationships with current and prospective teammates, patients, physicians, payors, suppliers and other business partners. Uncertainties related to the pending sale of DMG may impair our ability to attract, retain and motivate key personnel and could cause suppliers and other business partners to defer entering into contracts with us or seek to change existing business relationships with us. The loss or deterioration of significant business and operational relationships could have an adverse effect on our business, results of operations and financial condition. In addition, activities relating to the pending sale and related uncertainties could divert the attention of our management and other teammates from our day-to-day business or disrupt our operations in preparation for and during the post-closing separation of DMG. It is also possible that we could have stranded costs following the closing of the pending sale, which could be material. If we are unable to effectively manage these risks, our business, results of operations and financial condition may be adversely affected.

If we fail to complete the proposed sale of DMG, or if there is a significant delay in completing the sale, our business, results of operations, financial condition and stock price may be materially adversely affected.

The completion of the proposed sale of DMG is subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the approval of a notice of material modification by the California Department of Managed Health Care. If any condition to the closing of the sale of DMG is neither satisfied nor, where permissible, waived, the sale of DMG will not be completed. In addition, satisfying the closing conditions to the sale of DMG may take longer than expected. Regulators may impose material conditions, terms, obligations, costs or restrictions in connection with their approval of or consent to the sale of DMG, which could delay completion of the transaction, or if such approvals or consents are not obtained, could prevent completion of the transaction. There can be no assurance that all of the closing conditions will be satisfied or waived or that other events will not intervene to delay, or result in a failure to close, the sale of DMG. In addition, either we or Optum may terminate the equity purchase agreement if, among other things, the sale has not been consummated prior to September 5, 2018 (subject to a three-month extension that can be exercised by either party unilaterally). If the equity purchase agreement is terminated and our Board of Directors seeks an alternative transaction or another acquiror for the sale of the DMG business, we may not be able to negotiate a transaction with another party on terms comparable to, or better than, the terms of the equity purchase agreement with Optum.

If the sale of DMG is not completed for any reason, investor confidence could decline. A failed transaction may result in negative publicity and may affect our relationships with teammates, patients, physicians, payors, suppliers, regulators and other business partners. In addition, in the event of a failed transaction, we will have expended significant management resources in an effort to complete the sale, we have incurred additional debt in anticipation of receiving the sale proceeds but not have received the sale proceeds to repay such debt, and we will have incurred significant transaction costs, including legal fees, financial advisor fees and other related costs, without any commensurate benefit. Accordingly, if the proposed sale of DMG is not completed, or if there is a significant delay in completing the sale, our business, results of operations, financial condition and stock price may be materially adversely affected.

Our liquidity following the close of our pending sale of DMG and our planned subsequent entry into new external financing arrangements may be less than we anticipate, and we may use the proceeds from the pending sale of DMG and other available funds, including external financing and cash flow from operations, in ways that may not improve our results of operations or enhance the value of our common stock.

The purchase price for the sale of the DMG business is subject to customary adjustments, both upward and downward,which could be significant. Following the closing of the pending DMG sale, we plan to use sale proceeds and other available funds, including from external financing and cash flow from operations, to repay debt, make significant stockrepurchases and for general corporate purposes, which may include growth investments. A number of factors may impact our ability torepurchase stock and the timing of any such stock repurchases, including market conditions, the price of our common stock, our results of operations, cash flow and financial condition, available financing, leverage ratios, and legal, regulatory and contractual requirements and restrictions. Accordingly, the actual amount of common stock we repurchase may be less, perhaps substantially, and the period of time over which we make any stock repurchases may be substantially longer, than we currently anticipate. In addition, we may identify investments or other uses for our available funds (other than the ~~next several years~~DMG sale proceeds that we plan to use to repay debt) that we believe are more attractive than our current intended uses. Further, there can be no assurance that any investment will yield a favorable return.

Under the terms of the equity purchase agreement, we are subject to certain contractual restrictions while the sale of DMG is pending, and certain post-closing contractual obligations that, in some cases, could have a material adverse effect on our business, results of operations and financial condition.

Under the terms of the equity purchase agreement, we are subject to certain restrictions on the conduct of the DMG business prior to completing the sale of DMG, which may adversely affect our ability to execute certain of our business strategies, including the ability in certain cases to enter into or amend contracts, acquire or dispose of assets, incur indebtedness or incur capital expenditures. Such limitations could negatively affect our business and operations prior to the completion of the sale of DMG. Each of these risks may be exacerbated by delays or other adverse developments with respect to the completion of the sale of DMG.

In addition, we agreed to retain certain liabilities of the DMG business for which we have certain indemnification rights against the original 2012 HealthCare Partners (HCP) sellers. An escrow was established in connection with our acquisition of the DMG business from the HCP sellers as security for these indemnification rights, including with respect to the OIG investigation into certain patient diagnosis coding practices. We have submitted an indemnification claim against the sellers secured by the escrow for any and all liabilities incurred relating to these matters and intend to pursue recovery from the escrow. However, we ~~start-up or acquire new operations.~~

~~These risks~~can make no assurances that the indemnification and escrow will cover the full amount of our potential losses related to these matters, which could have a material adverse effect on our business, results of operations and financial condition.

Risk factors related to our U.S. dialysis and related lab services, ancillary services and strategic initiatives:

If patients in commercial plans are subject to restriction in plan designs or the average rates that commercial payors pay us decline significantly, it would have a material adverse effect on our business, results of operations and financial condition.

Approximately ~~33%~~31% of our U.S. dialysis and related lab services net revenues for the six months ended June 30, ~~2017~~2018, were generated from patients who have commercial payors (including hospital dialysis services) as their primary payor. The majority of these patients have insurance policies that pay us on terms and at rates that are generally significantly higher than Medicare rates. The payments we receive from commercial payors generate nearly all of our profit and all of our nonacute dialysis profits come from commercial payors. We continue to experience downward pressure on some of our commercial payment rates as a result of general conditions in the market, including as employers shift to less expensive options for medical services, recent and future consolidations among commercial payors, increased focus on dialysis services and other factors. In addition, many commercial payors that sell individual plans both on and off exchange have publicly announced losses in the marketplace. These payors may seek discounts on rates for marketplace plans on and off exchange. ~~There is no guarantee that commercial~~Commercial payment rates ~~will not~~could be materially lower in the future.

We continuously are ~~continuously~~ in the process of negotiating existing and potential new agreements with commercial payors who aggressively negotiate terms with us. Sometimes many significant agreements are being renegotiated at the same time. In the event that our continual negotiations result in overall commercial rate reductions in excess of overall commercial rate increases, the cumulative effect could have a material adverse effect on our business, results of operations and financial condition. Consolidations have significantly increased the negotiating leverage of commercial payors. Our negotiations with payors are also influenced by competitive pressures, and we may experience decreased contracted rates with commercial payors or experience decreases in patient volume as our negotiations with commercial payors continue. In addition to downward pressure on contracted commercial payor rates, payors have been attempting to design and implement plans to restrict access to coverage, and the duration and/or the breadth of benefits, which may result in decreased payments. In addition, payors have been attempting to impose restrictions and limitations on patient access to commercial exchange plans and non-contracted or out-of-network providers, and in some circumstances designate our centers as out-of-network providers. Rates for commercial exchange products and out-of-network providers are on average higher than rates for government products and in-network providers, respectively. ~~In 2017, a~~

A number of commercial payors have incorporated policies into their provider manuals limiting or refusing to accept charitable premium assistance from ~~bona fide~~ non-profit organizations, such as the American Kidney Fund, which may

impact the number of patients who are able to afford commercial exchange plans. Paying for coverage is a significant financial burden for many patients, and ESRD disproportionately affects the low-income population. Charitable premium assistance supports continuity of coverage and access to care for patients, many of whom are unable to continue working full-time as a result of their severe condition. A material restriction in patients' ability to access charitable premium assistance may restrict the ability of dialysis patients to obtain and maintain optimal insurance coverage, and may adversely impact a large number of dialysis

centers across the U.S. by making certain centers economically unviable, and may have a material adverse effect on our business, results of operations and financial condition.

We also believe commercial payors have or will begin to restructure their benefits to create disincentives for patients to stay with commercial insurance or to select or remain with out-of-network ~~providers and~~providers. In addition, payors may seek to decrease payment rates for out-of-network providers. Decreases in the number of patients with commercial ~~exchange~~ plans, decreases in out-of-network rates and restrictions on out-of-network access, our turning away new patients in instances where we are unable to come to agreement with commercial payors on rates, new business activities of commercial payors, or decreases in contracted rates could result in a significant decrease in our overall revenues derived from commercial payors. If the average rates that commercial payors pay us decline significantly, or if we see a decline in commercial patients, it would have a material adverse effect on our business, results of operations and financial condition. For additional details regarding specific risks we face regarding regulatory changes that could result in fewer patients covered under commercial plans or an increase of patients covered under more restrictive commercial plans with lower reimbursement rates, see the discussion in the risk factor under the heading ~~“Healthcare~~"Healthcare reform could have a material adverse effect on our business, financial condition and results of operations.”"

If the number of patients with higher-paying commercial insurance declines, it could have a material adverse effect on our business, results of operations and financial condition.

Our revenue levels are sensitive to the percentage of our patients with higher-paying commercial insurance coverage. A patient’s insurance coverage may change for a number of reasons, including changes in the patient’s or a family member’s employment status. ~~Many~~Any changes impacting our highest paying commercial payors will have a disproportionate impact on us. In addition, many patients with commercial and government insurance rely on financial assistance from charitable organizations, such as the American Kidney Fund. ~~However, certain~~Certain payors ~~are challenging~~have challenged our patients’ and other providers’ patients' ability to utilize assistance from charitable organizations for the payment of premiums, including through litigation and other legal proceedings. Regulators have also questioned the use of charitable premium assistance for ESRD patients, including CMS, which had issued an interim final rule on charitable premium assistance in December 2016. In January 2017, a federal district court in Texas issued a preliminary injunction on CMS’ interim final rule and in June 2017, at the request of CMS, the court stayed the proceedings while CMS conducts new rulemaking proceedings.patients. CMS or another regulatory agency or legislative authority may issue a new rule or guidance that challenges charitable premium assistance. If any of these challenges to kidney patients’ use of premium assistance are successful or restrictions are imposed on the use of financial assistance from such charitable organizations such that kidney patients are unable to obtain, or continue to receive or receive for a limited duration, such financial assistance, it could have a material adverse effect on our business, results of operations and financial condition. In addition, if our assumptions about how kidney patients will respond to any change in financial assistance from charitable organizations are incorrect, it could have a material adverse effect on our business, results of operations and financial condition.

When Medicare becomes the primary payor, the payment rate we receive for that patient decreases from the employer group health plan or commercial plan rate to the lower Medicare payment rate. The number of our patients who have government-based programs as their primary payors could increase and the percentage of our patients covered under commercial insurance plans could be negatively impacted as a result of improved mortality or declining macroeconomic conditions. To the extent there are sustained or increased job losses in the U.S., independent of whether general economic conditions improve, we could experience a decrease in the number of patients covered under commercial ~~plans.~~plans and/or an increase in uninsured and underinsured patients. We could also experience a further decrease in the payments we receive for services if changes to the healthcare regulatory system result in fewer patients covered under commercial plans or an increase of patients covered under more restrictive commercial plans with lower reimbursement rates. In addition, our continual negotiations with commercial payors under existing and potential new agreements could result in a decrease in the number of our patients covered by commercial plans to the extent that we cannot reach agreement with commercial payors on rates and other terms, resulting in termination or non-renewals of existing agreements and our inability to enter into new agreements. Commercial payors have taken and may continue to take steps to control the cost of and/or the eligibility for access to healthcare services, including relative to products on and off the healthcare exchanges. These efforts could impact the number of our patients who are eligible to enroll in commercial insurance plans, and remain on the plans, including plans offered through healthcare exchanges. Additionally, we continue to experience higher amounts of write-offs due to uninsured and underinsured patients, which has resulted in an increase in uncollectible accounts. Commercial payors could also cease paying in the primary position after providing 30 months of coverage resulting in a material reduction in payment as the patient moves to Medicare primary. If there is a significant reduction in the number of patients under higher-paying commercial plans relative to government-based programs that pay at lower rates or a significant increase in the number of patients that are uninsured and underinsured, it would have a material adverse effect on our business, results of operations and financial condition.

Changes in the structure of and payment rates under the Medicare ESRD program could have a material adverse effect on our business, results of operations and financial condition.

Approximately ~~42%~~44% of our U.S. dialysis and related lab services net revenues for the six months ended June 30, ~~2017~~2018, were generated from patients who have Medicare as their primary payor. For patients with Medicare coverage, all ESRD payments for dialysis treatments are made under a single bundled payment rate which provides a fixed payment rate to encompass all goods and services provided during the dialysis treatment that are related to the treatment of dialysis, including pharmaceuticals that were historically separately reimbursed to the dialysis providers, such as ~~EPO,~~erythropoietin (EPO), vitamin D analogs and iron supplements, irrespective of the level of pharmaceuticals administered or additional services ~~performed.~~performed, except in the case of calcimimetics, which are subject to a transitional drug add-on payment adjustment for the Medicare Part B ESRD payment. Most lab services are also included in the bundled payment. Under the ESRD ~~Prospective Payment System (PPS),~~PPS, the bundled payments to a dialysis facility may be reduced by as much as 2% based on the facility’s performance in specified quality measures set annually by CMS through the ESRD Quality Incentive Program, which

was established by the Medicare Improvements for Patients and Providers Act of 2008. The bundled payment rate is also adjusted for certain patient characteristics, a geographic usage index and certain other factors. In addition, the ESRD PPS is subject to rebasing, which can have a positive financial effect, or a negative one if the government fails to rebase in a manner that adequately addresses the costs borne by dialysis facilities. Similarly, as new drugs, services or labs are added to the ESRD bundle, CMS’ failure to adequately calculate the costs associated with the drugs, services or labs could have a material adverse effect on our business, results of operations and financial condition.

The current bundled payment system presents certain operating, clinical and financial risks, which include:

Risk that our rates are reduced by CMS. Uncertainty about future payment rates remains a material risk to our business. ~~Each year,~~

Risk that CMS, ~~publishes~~through its contracted Medicare Administrative Contractors (MACs) or otherwise, implements Local Coverage Determinations (LCDs) or other decisions that limit the frequency a ~~final rule~~provider can bill Medicare for ~~PPS,~~home dialysis treatments or other rules that may impact reimbursement. MACs have proposed drafts of LCDs to this effect. Such coverage determinations could have an adverse impact on our revenue. There is also risk commercial insurers could seek to incorporate the requirements or limitations associated with such LCDs into their contracted terms with dialysis providers, which ~~phases in the reductions~~could have an adverse impact on our revenue.

Risk that a MAC, or multiple MACs, change their interpretations of existing regulations, manual provisions and/or guidance; or seek to ~~the PPS base rate mandated by the American Taxpayer Relief Act of 2012 as modified by the Protecting Access to Medicare Act of 2014.~~implement or enforce new interpretations that are inconsistent with how we have interpreted existing regulations, manual provisions and/or guidance.

Risk that increases in our operating costs will outpace the Medicare rate increases we receive. We expect operating costs to continue to increase due to inflationary factors, such as increases in labor and supply costs, including increases in maintenance costs and capital expenditures to improve, renovate and maintain our facilities, equipment and information technology to meet changing regulatory requirements, regardless of whether there is a compensating inflation-based increase in Medicare payment rates or in payments under the bundled payment rate system.

Risk of federal budget sequestration cuts. As a result of the Budget Control Act of 2011 and the ~~Bipartisan Budget Act of 2015,~~BBA, an annual 2% reduction to Medicare payments took effect on April 1, 2013, and has been extended through ~~2025.~~2027. These across-the-board spending cuts have affected and will continue to adversely affect our business, results of operations and financial condition.

Risk that, if our clinical systems fail to accurately capture the data we report to CMS in connection with claims for which at least part of the government’s payments to us is based on clinical performance or patient outcomes or co-morbidities, we might be over-reimbursed by the government, which could subject us to certain liability. For example, CMS published a final rule that implemented a provision of the ACA, requiring providers to report and return Medicare and Medicaid overpayments within the later of (a) 60 days after the overpayment is identified, or (b) the date any corresponding cost report is due, if applicable. An overpayment impermissibly retained under this statute could subject us to liability under the FCA, exclusion from participation in the federal healthcare programs, and penalties under the federal Civil Monetary Penalty statute.

For additional details regarding the risks we face for failing to adhere to our Medicare and Medicaid regulatory compliance obligations, see the risk factor ~~below~~above under the heading ~~“If~~"If we fail to adhere to all of the complex government laws

and regulations that apply to our business, we could suffer severe consequences that could have a material adverse effect on our business, results of operations, financial condition and stock price.”"

Changes in state Medicaid or other non-Medicare government-based programs or payment rates could have a material adverse effect on our business, results of operations and financial condition.

Approximately 25% of our U.S. dialysis and related lab services net revenues for the six months ended June 30, ~~2017~~2018, were generated from patients who have state Medicaid or other non-Medicare government-based programs, such as coverage through the Department of Veterans Affairs (VA), as their primary coverage. As state governments and other governmental organizations face increasing budgetary pressure, we may in turn face reductions in payment rates, delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs. For example, certain state Medicaid programs and the VA have recently considered, proposed or implemented payment rate reductions.

The VA adopted Medicare’s bundled PPS pricing methodology for any veterans receiving treatment from non-VA providers under a national contracting initiative. Since we are a non-VA provider, these reimbursements are tied to a percentage of Medicare reimbursement, and we have exposure to any dialysis reimbursement changes made by CMS. Approximately 3% of our dialysis services revenues for the six months ended June 30, ~~2017~~2018 were generated by the VA.

In 2013, we entered into a five-year Nationwide Dialysis Services contract with the VA which is subject to one-year renewal periods, consistent with all provider agreements with the VA under this contract. During the length of the contract, the VA has elected not to make adjustments to reimbursement percentages that are tied to a percentage of Medicare reimbursement rates. These agreements provide the VA with the right to terminate the agreements without cause on short notice. Should the VA renegotiate, or not renew or cancel these agreements for any reason, we may cease accepting patients under this program and may be forced to close centers or experience lower reimbursement rates, which could have a material adverse effect on our business, results of operations and financial condition.

State Medicaid programs are increasingly adopting Medicare-like bundled payment systems, but sometimes these payment systems are poorly defined and are implemented without any claims processing infrastructure, or patient or facility adjusters. If these payment systems are implemented without any adjusters and claims processing changes, Medicaid payments will be substantially reduced and the costs to submit such claims may increase, which will have a negative impact on our business, results of operations and financial condition. In addition, some state Medicaid program eligibility requirements

mandate that citizen enrollees in such programs provide documented proof of citizenship. If our patients cannot meet these proof of citizenship documentation requirements, they may be denied coverage under these programs, resulting in decreased patient volumes and revenue. These Medicaid payment and enrollment changes, along with similar changes to other non-Medicare government programs could reduce the rates paid by these programs for dialysis and related services, delay the receipt of payment for services provided and further limit eligibility for coverage which could ~~materially adversely~~have a material adverse effect on our business, results of operations and financial condition.

Changes in clinical practices, payment rates or regulations impacting ~~EPO and other~~ pharmaceuticals could have a material adverse effect on our business, results of operations and financial condition and negatively impact our ability to care for patients.

Medicare bundles ~~EPO~~certain pharmaceuticals into the PPS ~~such that dosing variations do not change~~at industry average doses and prices. Any variation above the ~~amount paid~~industry average may be subject to a dialysis facility. Although some Medicaid programs and other payors suggest movement towards a bundled payment system inclusive of EPO, some non-Medicare payors continue to pay for EPO separately frompartial reimbursement through the ~~treatment rate.~~PPS outlier reimbursement policy.

Additionally, evaluations on the utilization and reimbursement for ESAs, which have occurred in the past and may occur in the future, and related actions by the U.S. Congress and federal agencies, could result in further restrictions on the utilization and reimbursement for ESAs. Commercial payors have increasingly examined their administration policies for ~~EPO~~pharmaceuticals and, in some cases, have modified those policies. Changes in labeling of ~~EPO and other~~ pharmaceuticals in a manner that alters physician practice patterns, ~~whom are the ultimate determiners of EPO~~including their independent determinations as to appropriate dosing, or accepted clinical practices, and/or changes in private and governmental payment criteria, including the introduction of ~~EPO~~ administration policies could have a material adverse effect on our business, results of operations and financial condition. Further increased utilization of ~~EPO~~certain pharmaceuticals for patients for whom the cost of ~~EPO~~which is included in a bundled reimbursement rate, or further decreases in reimbursement for ~~EPO and other~~ pharmaceuticals that are not included in a bundled reimbursement rate, could also have a material adverse effect on our business, results of operations and financial condition.

Additionally, as of January 1, 2018, calcimimetics became part of the Medicare Part B ESRD payment, but subject to its transitional drug add-on payment adjustment. We implemented processes designed to provide the drug as required under the applicable regulations and prescribed by physicians and have entered into agreements to provide for access to and distribution of the drug. If payors do not pay as anticipated, if we are not adequately reimbursed for the cost of the drug, or the processes we have implemented to provide the drug do not perform as anticipated, then we could be subject to both financial and operational risk, among other things.

We may be subject to increased inquiries or audits from a variety of governmental bodies or claims by third parties. Although we believe our anemia management practices and other pharmaceutical administration practices have been compliant with existing laws and regulations, increased inquiries or audits from governmental bodies or claims by third parties, which would require management’s attention and could result in significant legal expense. Any negative findings could result in substantial financial penalties or repayment obligations, the imposition of certain obligations on and changes to our practices and procedures as well as the attendant financial burden on us to comply with the obligations, or exclusion from future participation in the Medicare and Medicaid programs, and could have a material adverse effect on our business, results of operations and financial condition.

If we fail to comply with our Corporate Integrity Agreement, we could be subject to substantial penalties and exclusion from participation in federal healthcare programs that could have a material adverse effect on our business, results of operations and financial condition.

In October 2014, we entered into a Settlement Agreement with the United States and relator David Barbetta to resolve the then pending 2010 and 2011 U.S. Attorney physician relationship investigations and paid $406 million in settlement amounts, civil forfeiture, and interest to the United States and certain states. In connection with the resolution of these matters, and in exchange for the OIG’s agreement not to exclude us from participating in the federal healthcare programs, we have entered into a five-year CIA with the OIG. The CIA (i) requires that we maintain certain elements of our compliance programs; (ii) imposes certain expanded compliance-related requirements during the term of the CIA; (iii) requires ongoing monitoring and reporting by an independent monitor, imposes certain reporting, certification, records retention and training obligations, allocates certain oversight responsibility to the Board’s Compliance Committee, and necessitates the creation of a Management Compliance Committee and the retention of an independent compliance advisor to the Board; and (iv) contains certain business restrictions related to a subset of our joint venture arrangements, including our agreeing to (1) unwind 11 joint venture transactions that were created through partial divestitures to, or partial acquisitions from, nephrologists, and that cover 26 of our 2,119 clinics that existed at the time we entered into the Settlement Agreement, all of which have been completed, (2) not enter into certain types of partial divestiture joint venture transactions with nephrologists during the term of the CIA, (3) non-enforcement of certain patient-related non-solicitation restrictions, and (4) certain other restrictions. The costs associated with compliance with the CIA could be substantial and may be greater than we currently anticipate. In addition, in the event of a breach of the CIA, we could become liable for payment of certain stipulated penalties, and could be excluded from participation in federal healthcare programs. The OIG has notified us in the past that it considered us to be ~~previously~~ in breach of the CIA, ~~because of three implementation deficiencies. While we have remediated the deficiencies~~ and ~~have paid certain stipulated penalties,~~ we cannot provide any assurances that we may not be found in breach of the CIA in the future. In general, the costs associated with compliance with the CIA, or any liability or consequences associated with a breach, could have a material adverse effect on our

business, results of operations and financial condition. For our domestic dialysis business, we are required under the CIA to report to the OIG (i) probable violations of criminal, civil or administrative laws applicable to any federal health care program for which penalties or exclusions may be authorized under applicable laws and regulations; (ii) substantial overpayments of amounts of money we have received in excess of the amounts due and payable under the federal healthcare program requirements; and (iii) employment of or contracting with individuals ineligible from participating in the federal healthcare programs (we refer to these collectively as Reportable Events). We have provided the OIG notice of Reportable Events, and we may identify and report additional events in the future. If any of our operations are found to violate government laws and regulations, we could suffer severe consequences that could have a material adverse effect on our business, results of operations, financial condition and stock price, including those consequences described under the risk factor ~~“If~~"If we fail to adhere to all of the complex government laws and regulations that apply to our business, we could suffer severe consequences that could have a material adverse effect on our business, results of operations, financial condition and stock price.”"

Delays in state Medicare and Medicaid certification or other licensing and/or anything impacting the licensing of our dialysis centers could adversely affect our business, results of operations and financial condition.

Before we can begin billing for patients treated in our outpatient dialysis centers who are enrolled in government-based programs, we are required to obtain state and federal certification for participation in the Medicare and Medicaid programs. As state agencies responsible for surveying dialysis centers on behalf of the state and Medicare program face increasing budgetary pressure, certain states are having difficulty keeping up with certifying dialysis centers in the normal course resulting in significant delays in certification. If state governments continue to have difficulty keeping up with certifying new centers in the normal course and we continue to experience significant delays in our ability to treat and bill for services provided to patients covered under government programs, it could cause us to incur write-offs of investments or accelerate the recognition of lease obligations in the event we have to close centers or our centers’ operating performance deteriorates, and it could have an adverse effect on our business, results of operations and financial condition. Although the BBA passed in February 2018 allows organizations approved by the Department of Health and Human Services (HHS) to accredit dialysis facilities and imposes certain timing requirements regarding the initiation of initial surveys to determine if certain conditions and requirements for payment have been satisfied, we cannot predict the ultimate impact of these changes. In addition to certifications for Medicare and Medicaid, some states have licensing requirements for ESRD facilities. Delays in licensure, denials of licensure, or ~~denials~~withdrawal of licensure could also adversely affect our business, results of operations and financial condition.

If our joint ventures were found to violate the law, we could suffer severe consequences that would have a material adverse effect on our business, results of operations and financial condition.

As of June 30, ~~2017,~~2018, we owned a controlling interest in numerous dialysis-related joint ventures, which represented approximately ~~24%~~25% of our net U.S. dialysis and related lab services net revenues for the six months ended June 30, ~~2017.~~2018. In addition, we also owned noncontrolling equity investments in several other dialysis related joint ventures. We may continue to increase the number of our joint ventures. Many of our joint ventures with physicians or physician groups also have certain physician owners providing medical director services to centers we own and operate. Because our relationships with physicians are governed by the federal and state anti-kickback statutes, we have sought to structure our joint venture arrangements to satisfy as many federal safe harbor requirements as we believe are commercially reasonable. ~~However, although our~~Our joint venture arrangements do not satisfy all of the elements of any safe harbor under the federal Anti-Kickback Statute, ~~they are not automatically prohibited under the federal Anti-Kickback Statute but~~however, and therefore are susceptible to government scrutiny. For example, in October 2014, we entered into a ~~Settlement Agreement with the United States and relator David Barbetta~~settlement agreement to resolve the then pending 2010 and 2011 U.S. Attorney physician relationship investigations regarding certain of our joint ventures and paid $406 million in settlement amounts, civil forfeiture, and interest to the United States and certain states. For further details on the settlement agreement, see ~~“If~~"If we fail to comply with our Corporate Integrity Agreement, we could be subject to substantial penalties and exclusion from participation in federal healthcare programs that could have a material adverse effect on our business, results of operations and financial ~~condition”~~condition".

There are significant ~~estimating~~ risks associated with estimating the amount of dialysis revenues and related refund liabilities that we recognize, and if our estimates of revenues and related refund liabilities are materially inaccurate, it could impact the timing and the amount of our revenues recognition or have a material adverse effect on our business, results of operations and financial condition.

There are significant ~~estimating~~ risks associated with estimating the amount of U.S. dialysis and related lab services revenues and related refund liabilities that we recognize in a reporting period. The billing and collection process is complex due to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage and other payor issues. Determining applicable primary and secondary coverage for approximately ~~194,600~~200,500 U.S. patients at any point in time, together with the changes in patient coverage that occur each month, requires complex, resource-intensive processes. Errors in determining the correct coordination of benefits may result in refunds to payors. Revenues associated with Medicare and Medicaid programs are also subject to estimating risk related to the amounts not paid by the primary government payor that will ultimately be collectible from other government programs paying secondary coverage, the patient’s commercial health plan

secondary coverage or the patient. Collections, refunds and payor retractions typically continue to occur for up to three years and longer after services are provided. We generally expect our range of U.S. dialysis and related lab services revenues estimating risk to be within 1% of net revenues for the segment. If our estimates of U.S. dialysis and related lab services revenues and related refund liabilities are materially inaccurate, it could impact the timing and the amount of our revenues recognition and have a material adverse impact on our business, results of operations and financial condition.

Our ancillary services and strategic initiatives, including our pharmacy services and our international ~~dialysis~~ operations, that we operate or invest in now or in the future may generate losses and may ultimately be unsuccessful. In the event that one or more of these activities is unsuccessful, our business, results of operations and financial condition may be negatively impacted and we may have to write off our investment and incur other exit costs.

Our ancillary services and strategic initiatives currently include pharmacy services, disease management services, vascular access services, ESRD clinical research programs, physician services, physician practice management services, direct primary careare subject to many of the same risks, regulations and laws, as described in the risk factors related to our ~~international~~ dialysis ~~operations.~~business set forth in this Part II, Item 1A, and are also subject to additional risks, regulations and laws specific to the nature of the particular strategic initiative. We expect to add additional service offerings to our business and pursue additional strategic initiatives in the future as circumstances warrant, which could include healthcare services not related to dialysis. Many of these initiatives require or would require investments of both management and financial resources and can generate significant losses for a substantial period of time and may not become ~~profitable.~~profitable in the expected timeframe or at all. There can be no assurance that any such strategic initiative will ultimately be successful. Any significant change in market conditions, or business performance, or in the political, legislative or regulatory environment, may impact the economic viability of any of these strategic initiatives. For example, recent changes in the oral pharmacy space, including reimbursement rate pressures, have negatively impacted the economics of our pharmacy services business. As a result, during the second half of 2018 we plan to transition the customer service and fulfillment functions of this business to third parties and wind down our distribution operation. We expect to incur a loss for these operations during the transition in the third and fourth quarters of 2018, and we incurred a one-time charge related to write-off of assets in the second quarter of 2018. We also expect to incur additional restructuring charges in the remainder of 2018 related to this plan.

If any of our ancillary services or strategic initiatives, including our ~~pharmacy services and our~~ international ~~dialysis~~ operations, ~~do not perform as planned,~~are unsuccessful, it ~~could~~would have a negative impact on our business, results of operations and financial condition, and we may determine to exit that line of

business. We could incur significant termination costs if we were to exit certain of these lines of business. In addition, we may incur a material write-off or an impairment of our investment, including goodwill, in one or more of ~~these activities,~~our ancillary services or strategic initiatives. In that regard, we ~~could incur significant termination costs if we were~~have taken, and may in the future take, impairment and restructuring charges in addition to ~~exit a certain line of business.~~those described above related to our ancillary services and strategic initiatives, including in our international and pharmacy businesses.

If a significant number of physicians were to cease referring patients to our dialysis centers, whether due to regulatory or other reasons, it would have a material adverse effect on our business, results of operations and financial condition.

~~We believe that~~Physicians, including medical directors, choose where they refer their patients. Some physicians prefer to have their patients treated at dialysis centers where they or other members of their practice supervise the overall care provided as medical director of the center. As a result, ~~the primary~~ referral ~~source~~sources for ~~most~~many of our centers ~~is often~~include the physician or physician group providing medical director services to the center.

Our medical director contracts are for fixed periods, generally ten years, and at any given time a large number of them could be up for renewal at the same time. Medical directors have no obligation to extend their agreements with us and if we are unable to enforce noncompetition provisions contained in terminated medical director agreements, our former medical directors may choose to provide medical director services for competing providers or establish their own dialysis centers in competition with ours. Neither our current nor former medical directors have an obligation to refer their patients to our centers.

The aging of the nephrologist population and opportunities presented by our competitors may negatively impact a medical director’s decision to enter into or extend his or her agreement with us. ~~Different~~Moreover, different affiliation models in the changing healthcare environment that limit a nephrologist’s choice in where he or she can refer patients, such as an increase in the number of physicians becoming employed by hospitals or a perceived decrease in the quality of service levels at our centers, may limit a nephrologist’s ability or desire to refer patients to our centers or otherwise negatively impact treatment volumes.

In addition, we may take actions to restructure existing relationships or take positions in negotiating extensions of relationships to assure compliance with the federal Anti-Kickback Statute, Stark Law and other similar laws. If the terms of any existing agreement are found to violate applicable laws, we may not be successful in restructuring the relationship, which could lead to the early termination of the ~~agreement, or cause the physician to stop referring patients to our dialysis centers.~~agreement. These actions, in an effort to comply with applicable laws and regulations, could negatively impact the decision of physicians to extend their medical director agreements with ~~us or~~us. If we are unable to obtain qualified medical directors to provide supervision of the operations and care provided at our dialysis centers, it could affect physicians’ desire to refer ~~their~~ patients to ~~us.~~our dialysis centers. If a significant number of physicians were to cease referring patients to our dialysis centers, it would have a material adverse effect on our business, results of operations and financial condition.

If ~~there are~~our labor costs continue to rise, including due to shortages, ofchanges in certification requirements and higher than normal turnover rates in skilled clinical personnel, or ~~if changes to state staffing ratios are implemented with which we are required to comply,~~currently pending or future requirements impose additional requirements or limitations on our operations or profitability, we may experience disruptions in our business operations and increases in operating expenses, among other things, which could have a material adverse effect on our business, results of operations and financial condition.

We ~~are experiencing~~face increasing labor costs generally, and in particular, we face increased labor costs and difficulties in hiring nurses due to a nationwide shortage of skilled clinical personnel. We compete for nurses with hospitals and other healthcare providers. This nursing shortage may limit our ability to

expand our operations. Furthermore, changes in certification requirements can impact our ability to maintain sufficient staff levels, including to the extent our teammates are not able to meet new requirements, among other things. In addition, if we experience a higher than normal turnover rate for our skilled clinical personnel, our operations and treatment growth may be negatively impacted, which could adversely affect our business, results of operations and financial condition.

In addition, currently ~~proposed and/~~pending and potential future ballot initiatives or ~~future~~referendums, legislation or policy changes could cause us to incur substantial costs to challenge and prepare for and, if implemented, impose additional requirements on our operations, including increases in the required staffing levels or staffing ratios for clinical personnel. For example, SB 349 is a bill that was introduced in the California legislature that, if passed and signed into law in its current form, would among other things mandate staffing ratios for nurses, technicians, dietitians, and social workers as well aspersonnel, minimum transition times between ~~treatments. These~~treatments, limits on how much patients may be charged for care, limitations as to the amount that can be spent on certain medical costs, and a ceiling on the percent of profit for such care. Changes such as those mandated by currently pending and future ballot initiatives or referendums, legislation or policy changes would likely materially reduce our revenues and increase our operating expense and impact our ability to staff our clinics to the new, elevated staffing levels, in particular given the ongoing nationwide shortage of healthcare workers, especially nurses. Any of these events or circumstances could materially reduce our revenues and increase our operating and other costs, require us to close existing or not build new dialysis centers, or reduce shifts or negatively impact employee relations, treatment growth and productivity, and could have a material

adverse effect on our business, results of operations and financial condition. For additional information on these risks, see "Changes in federal and state health regulations could have a material adverse effect on our ~~employee relations, treatment growth, productivity,~~ business, financial condition and results of ~~operations and financial condition.~~operations."

Our business is labor intensive and could be materially adversely affected if we are unable to ~~maintain satisfactory relations with our~~attract and retain employees or if union organizing activities or legislative changes result in significant increases in our operating costs or decreases in productivity.

Our business is labor intensive, and our financial and operating results ~~are~~have been and continue to be subject to variations in labor-related costs, productivity and the number of pending or potential claims against us related to labor and employment practices. Political or other efforts at the national or local level could result in actions or proposals that increase the likelihood or success of union organizing activities at our facilities and ongoing union organizing activities at our facilities could continue or increase for other reasons. ~~Labor~~We could experience an upward trend in wages and benefits and labor and employment claims, including the filing of class action suits, or ~~work stoppages, wages and benefits or~~ adverse outcomes of ~~these types of~~such claims, ~~could trend upwards.~~or face work stoppages. In addition, we are and may continue to be subject to targeted corporate campaigns by union organizers in response to which we may be required to expend resources, both time and financial. Any of these events or circumstances could have a material adverse effect on our employee relations, treatment growth, productivity, business, results of operations and financial condition.

Complications associated with our billing and collections system could materially adversely affect our business, results of operations and financial condition.

Our billing system is critical to our billing operations. If there are defects in the billing system, we may experience difficulties in our ability to successfully bill and collect for services rendered, including a delay in collections, a reduction in the amounts collected, increased risk of retractions from and refunds to commercial and government payors, an increase in our provision for uncollectible accounts receivable and noncompliance with reimbursement regulations, any or all of which could materially adversely affect our results of operations.

Risk factors primarily related to DMG:

DMG is subject to many of the same risks to which our dialysis business is subject.

As a participant in the healthcare industry, DMG is subject to many of the same risks as our dialysis business is, as described in the risk factors set forth above in this Part I,II, Item 1A, any of which could have a material adverse effect on DMG’s business, results of operations and financial condition.

Under most of DMG’s agreements with health plans, DMG assumes some or all of the risk that the cost of providing services will exceed its compensation.

Approximately ~~83%~~84% of DMG’s revenue for the six months ended June 30, ~~2017~~2018 is derived from fixed per member per month (PMPM) fees paid by health plans under capitation agreements with DMG or its associated physician groups. While there are variations specific to each arrangement, DMG, through ~~DaVita Health Plan of California, Inc. (DHPC),~~DHPC, a subsidiary of HealthCare Partners Holdings, LLC and a restricted Knox-Keene licensed entity, and, in certain instances, DMG’s associated physician groups, generally contract with health plans to receive a PMPM fee for professional services and assume the financial responsibility for professional services only. In some cases, the health plans separately enter into capitation contracts with third parties (typically hospitals) who receive directly a PMPM fee and assume contractual financial responsibility for hospital services. In other cases, the health plan does not pay any portion of the PMPM fee to the hospital, but rather administers claims for hospital expenses itself. In both scenarios, DMG enters into managed care-related administrative services agreements or similar arrangements with those third parties (typically hospitals) under which DMG agrees to be responsible for utilization review, quality assurance, and other managed care-related administrative functions and claim payments. As compensation for such administrative services, DMG is entitled to receive a percentage of the amount by which the institutional capitation revenue received from health plans exceeds institutional expenses; any such risk-share amount to which DMG is entitled is recorded as medical revenues, and DMG is also responsible for a percentage of any short-fall in the event that institutional

expenses exceed institutional revenues. To the extent that members require more care than is anticipated and/or the cost of care increases, aggregate fixed PMPM amounts, or capitation payments, may be insufficient to cover the costs associated with treatment. If medical costs and expenses exceed estimates, except in very limited circumstances, DMG will not be able to increase the PMPM fee received under these risk agreements during their then-current terms and could, directly or indirectly through its contracts with its associated physician groups, suffer losses with respect to such agreements.

Changes in DMG’s or its associated physician groups’ anticipated ratio of medical expense to revenue can significantly impact DMG’s financial results. Accordingly, the failure to adequately predict and control medical costs and expenses and to make reasonable estimates and maintain adequate accruals for incurred but not reported claims, could have a material adverse effect on DMG’s business, results of operations and financial condition.

Historically, DMG’s and its associated physician groups’ medical costs and expenses as a percentage of revenue have fluctuated. Factors that may cause medical expenses to exceed estimates include:

the health status of members;

higher than expected utilization of new or existing healthcare services or technologies;

an increase in the cost of healthcare services and supplies, including pharmaceuticals, whether as a result of inflation or otherwise;

changes to mandated benefits or other changes in healthcare laws, regulations and practices;

periodic renegotiation of provider contracts with specialist physicians, hospitals and ancillary providers;

periodic renegotiation of contracts with DMG’s affiliated primary care physicians and specialists;

changes in the demographics of the participating members and medical trends;

contractual or claims disputes with providers, hospitals or other service providers within and outside of a health plan’s network;

the occurrence of catastrophes, major epidemics or acts of terrorism; and

the reduction of health plan premiums.

Risk-sharing arrangements that DMG and its associated physician groups have with health plans and hospitals could result in their costs exceeding the corresponding revenues, which could reduce or eliminate any shared risk profitability.

Most of the agreements between health plans and DMG and its associated physician groups contain risk-sharing arrangements under which the physician groups can earn additional compensation from the health plans by coordinating the provision of quality, cost-effective healthcare to members. However, such arrangements may require the physician group to assume a portion of any loss sustained from these arrangements, thereby reducing DMG’s net income. Under these risk-sharing arrangements, DMG and its associated physician groups are responsible for a portion of the cost of hospital services or other services that are not capitated. The terms of the particular risk-sharing arrangement allocate responsibility to the respective parties when the cost of services exceeds the related revenue, which results in a deficit, or permit the parties to share in any surplus amounts when actual costs are less than the related revenue. The amount of non-capitated medical and hospital costs in any period could be affected by factors beyond the control of DMG, such as changes in treatment protocols, new technologies, longer lengths of stay by the patient and inflation. Certain of DMG’s agreements with health plans stipulate that risk-sharing pool deficit amounts are carried forward to offset any future years’ surplus amounts DMG would otherwise be entitled to receive. DMG accrues for any such risk-sharing deficits. To the extent that such non-capitated medical and hospital costs are higher than anticipated, revenue may not be sufficient to cover the risk-sharing deficits ~~the health plans~~DMG and ~~DMG~~its associated physician groups are responsible for, which could have a material adverse effect on DMG’s business, results of operations and financial condition.

Renegotiation, renewal or termination of capitation agreements with health plans could have a material adverse effect on DMG’s business, results operations and financial condition.

Under most of DMG’s and its associated physician groups’ capitation agreements with health plans, the health plan is generally permitted to modify the benefit and risk obligations and compensation rights from time to time during the terms of the agreements. If a health plan exercises its right to amend its benefit and risk obligations and compensation rights, DMG and its associated physician groups are generally allowed a period of time to object to such amendment. If DMG or its associated physician group so objects, under some of the risk agreements, the relevant health plan may terminate the applicable agreement upon 90 to 180 days written notice. If DMG or its associated physician groups enter into capitation contracts or other risk sharing arrangements with unfavorable economic terms, or a capitation contract is amended to include unfavorable terms, DMG could, directly or indirectly through its contracts with its associated physician groups, suffer losses with respect to such

contract. Since DMG does not negotiate with CMS or any health plan regarding the benefits to be provided under their Medicare Advantage plans, DMG often has just a few months to familiarize itself with each new annual package of benefits it is expected to offer. Depending on the health plan at issue and the amount of revenue associated with the health plan’s risk agreement, the renegotiated terms or termination could have a material adverse effect on DMG’s business, results of operations and financial condition.

If DMG’s agreements or arrangements with any physician equity holder(s) of associated physicians, physician groups or ~~IPAs~~independent practice associations (IPAs) are deemed invalid under state law, including laws against the corporate practice of medicine, or federal law, or are terminated as a result of changes in state law, or if there is a change in accounting standards by the Financial Accounting Standards Board (FASB) or the interpretation thereof affecting consolidation of entities, it could have a material adverse effect on DMG’s consolidation of total revenues derived from such associated physician groups.

DMG’s financial statements are consolidated in accordance with applicable accounting standards and include the accounts of its majority-owned subsidiaries and certain non-owned DMG-associated and managed physician groups. Such consolidation for accounting and/or tax purposes does not, is not intended to, and should not be deemed to, imply or provide to DMG any control over the medical or clinical affairs of such physician groups. In the event of a change in accounting standards promulgated by FASB or in interpretation of its standards, or if there is an adverse determination by a regulatory agency or a court, or a change in state or federal law relating to the ability to maintain present agreements or arrangements with such physician groups, DMG may not be permitted to continue to consolidate the total revenues of such organizations. A change in accounting for consolidation with respect to DMG’s present agreement or arrangements would diminish DMG’s reported revenues but would not be expected to materially and adversely affect its reported results of operations, while regulatory or legal rulings or changes in law interfering with DMG’s ability to maintain its present agreements or arrangements could materially diminish both revenues and results of operations.

If DHPC is not able to satisfy financial solvency or other regulatory requirements, we could become subject to sanctions and its license to do business in California could be limited, suspended or terminated, which could have a material adverse effect on DMG’s business, results of operations and financial condition.

Knox-Keene requires healthcare service plans operating in California to comply with financial solvency and other requirements overseen by the California Department of Managed HealthCare (DMHC). Under Knox-Keene, DHPC is required to, among other things:

Maintain, at all times, a minimum tangible net equity (TNE);

Submit periodic financial solvency reports to the DMHC containing various data regarding performance and financial solvency;

Comply with extensive regulatory requirements; and

Submit to periodic regulatory audits and reviews concerning DHPC operations and compliance with Knox-Keene.

In the event that DHPC is not in compliance with the provisions of Knox-Keene, we could be subject to sanctions, or limitations on, or suspension of its license to do business in California, which could have a material adverse effect on DMG’s business, results of operations and financial condition.

If DMG’s associated physician group is not able to satisfy the California DMHC’s financial solvency requirements, DMG’s associated physician group could become subject to sanctions and DMG’s ability to do business in California could be limited or terminated, which could have a material adverse effect on DMG’s business, results of operations and financial condition.

The California DMHC has instituted financial solvency regulations to monitor the financial solvency of capitated physician groups. Under these regulations, DMG’s associated physician group is required to, among other things:

Maintain, at all times, a minimum cash-to-claims ratio (where cash-to-claims ratio means the organization’s cash, marketable securities and certain qualified receivables, divided by the organization’s total unpaid claims liability). The regulation currently requires a cash-to-claims ratio of 0.75.

Submit periodic reports to the California DMHC containing various data and attestations regarding performance and financial solvency, including incurred but not reported calculations and documentation, and attestations as to whether or not the organization was in compliance with Knox-Keene requirements related to claims payment timeliness, had maintained positive TNE (i.e., at least $1.00) and had maintained positive working capital (i.e., at least $1.00).

In the event that DMG’s associated physician group is not in compliance with any of the above criteria, DMG’s associated physician group could be subject to sanctions, or limitations on, or ~~removal~~termination of, its ability to do business in California, which could have a material adverse effect on DMG’s business, results of operations and financial condition.

Reductions in Medicare Advantage health plan reimbursement rates stemming from ~~recent~~ healthcare reforms and any future related regulations could have a material adverse effect on DMG’s business, results of operations and financial condition.

A significant portion of DMG’s revenue is directly or indirectly derived from the monthly premium payments paid by CMS to health plans for medical services provided to Medicare Advantage enrollees. As a result, DMG’s results of operations are, in part, dependent on government funding levels for Medicare Advantage programs. Any changes that limit or reduce Medicare Advantage reimbursement levels, such as reductions in or limitations of reimbursement amounts or rates under programs, reductions in funding of programs, expansion of benefits without adequate funding, elimination of coverage for certain benefits, or elimination of coverage for certain individuals or treatments under programs, could have a material adverse effect on DMG’s business, results of operations and financial condition.

Each year, CMS issues a final rule to establish the Medicare Advantage benchmark payment rates for the following calendar year. Any reduction to Medicare Advantage rates toimpacting DMG that is greater compared to the industry average rate may have a material adverse effect on DMG’s business, results of operations and financial condition. The final impact of the Medicare Advantage rates can vary from any estimate we may have and may be further impacted by the relative growth of DMG’s Medicare Advantage patient volumes across markets as well as by the benefit plan designs submitted. It is possible that we may underestimate the impact of the Medicare Advantage rates on our business, which could have a material adverse effect on DMG’s business, results of operations and financial condition.

We ~~have taken~~took impairment charges against the goodwill of several of our DMG reporting units in ~~four~~five of the ~~seven~~eleven quarters since the fourth quarter of 2015 based on continuing developments in our DMG business, including recent annual updates to Medicare Advantage benchmark reimbursement rates, changes in our expectations concerning future government reimbursement rates and our expected ability to mitigate them, medical cost and utilization trends, commercial pricing pressures, commercial membership rates, underperformance of certain at-risk reporting units and other market ~~conditions.~~factors. We may also need to take additional ~~goodwill~~ impairment charges against earnings in a future period, depending on the impact of continuing developments on the value of our DMG ~~reporting units. A goodwill impairment occurs when~~business. Specifically, if DMG’s fair value less the costs incurred in the sale of DMG falls below its carrying amount, ~~of a reporting unit’s goodwill is in excess of its implied fair value,~~we may need to recognize additional impairment charges on this business, and the amount of such ~~non-cash charge,~~charges, if any, could be significant. ~~In estimating~~Our estimates of the fair value of our DMG reporting units, we update our forecasts for our at-risk DMG reporting units to reflect the expected future cash flows that we believe market participants would use in determining fair values of our DMG reporting units if they were to acquire these businesses. We and our independent advisors also usethis business rely on certain estimates and ~~key~~ assumptions, ~~in determining~~including the ~~estimate~~terms and pricing agreed for the sale of ~~these fair values, including~~this business, as well as applicable market multiples, discount and long-term growth rates, market data and future reimbursement ~~rates.~~rates, as applicable. Our estimates of the fair value of ~~our~~the DMG ~~reporting units~~business could differ from the actual ~~values~~value that a market participant would pay for ~~these reporting units.~~this business.

DMG’s Medicare Advantage revenues may continue to be volatile in the future, which could have a material adverse impact on DMG’s business, results of operations and financial ~~condition~~condition.

The ACA contains a number of provisions that negatively impact Medicare Advantage plans, each of which could have a material adverse effect on DMG’s business, results of operations and financial condition. These provisions include the following:

Medicare Advantage benchmarks for 2011 were frozen at 2010 levels. From 2012 through 2016, Medicare Advantage benchmark rates were phased down from prior levels. The new benchmarks ~~will be~~were fully phased-in in 2017 and ~~will~~ range between 95% and 115% of the Medicare ~~FFS~~Fee-for-Service (Medicare FFS) costs, depending on a plan’s geographic area. If our costs escalate faster than can be absorbed by the level of revenues implied by these benchmark rates, then it could have a material adverse effect on DMG’s business and results of operations.

Rebates received by Medicare Advantage plans that were reduced, with larger reductions for plans failing to receive certain quality ratings.

The Secretary of the ~~Department of Health and Human Services (HHS)~~HHS has been granted the explicit authority to deny Medicare Advantage plan bids that propose significant increases in cost sharing or decreases in benefits. If the bids submitted by plans contracted with DMG are denied, this could have a material adverse effect on DMG’s business and results of operations.

Medicare Advantage plans with medical loss ratios below 85% are required to pay a rebate to the Secretary of HHS. The rebate amount is the total revenue under the contract year multiplied by the difference between 85% and the plan’s actual medical loss ratio. The Secretary of HHS will halt enrollment in any plan failing to meet this ratio for three consecutive years, and terminate any plan failing to meet the ratio for five consecutive years. If a DMG-contracting Medicare Advantage plan experiences a limitation on enrollment or is otherwise terminated from the Medicare Advantage program, it could have a material adverse effect on DMG’s business and results of operations.

Prescription drug plans are required to provide coverage of certain drug categories on a list developed by the Secretary of HHS, which could increase the cost of providing care to Medicare Advantage enrollees, and thereby reduce DMG’s revenues and earnings. The Medicare Part D premium amount subsidized for high-income beneficiaries has been reduced, which could lower the number of Medicare Advantage enrollees, which would have a negative impact on DMG’s business and results of operations.

CMS increased coding intensity adjustments for Medicare Advantage plans beginning in 2014 and continuing through 2018, which reduces CMS payments to Medicare Advantage plans, which in turn will likely reduce the amounts payable to DMG and its associated physicians, physician groups, and IPAs under its capitation agreements.

~~The 2016 Presidential~~Recent legislative and ~~Congressional elections, and recent legislative~~executive efforts to enact further healthcare reform legislation have caused the future state of the exchanges, ~~and~~ other ACA reforms, and many core aspects of the current U.S. health care system to be unclear. While specific changes and their timing are not yet apparent, enacted reforms and future legislative, regulatory, or executive changes could have a material adverse effect on DMG’s business, results of operations and financial condition.

There is also uncertainty regarding both Medicare Advantage payment rates and beneficiary enrollment, which, if reduced, would reduce DMG’s overall revenues and net income. For example, although the Congressional Budget Office (CBO) predicted in 2010 that Medicare Advantage participation would drop substantially by 2020, the CBO has more recently predicted, without taking into account potential future reforms, that enrollment in Medicare Advantage (and other contracts covering Medicare Parts A and B) could reach 31 million by 2027. Although Medicare Advantage enrollment increased by approximately 5.6 million, or by 50%, between the enactment of the ACA in 2010 and 2015, there can be no assurance that this trend will continue. Further, fluctuation in Medicare Advantage payment rates are evidenced by CMS’s annual announcement of the expected average change in revenue from the prior year: for ~~2017,~~2018, CMS announced an average increase of ~~0.85%~~0.45%; and for ~~2018, 0.45%~~2019, 1.8%. Uncertainty over Medicare Advantage enrollment and payment rates present a continuing risk to DMG’s business.

According to the Kaiser Family Foundation (KFF), Medicare Advantage enrollment continues to be highly concentrated among a few payors, both nationally and in local ~~markets.~~regions. In 2017, the KFF reported that three payors together ~~account~~accounted for more than half of Medicare Advantage ~~enrollment;~~enrollment and eight firms ~~account~~accounted for approximately 75% of the ~~market; and in 439~~lives. In 441 counties in ~~26 states,~~2018, only one company ~~offers~~will offer Medicare Advantage ~~plans, an indicator that those markets may lack competition. In 2016 and 2017, mergers between major Medicare Advantage carriers have been subject to regulatory review.~~plans. Consolidation among Medicare Advantage plans in certain regions, or the Medicare program’s failure to attract additional plans to participate in the Medicare Advantage program, could have a material adverse effect on DMG’s business, results of operations and financial condition.

DMG’s operations are dependent on competing health plans and, at times, a health plan’s and DMG’s economic interests may diverge.

For the six months ended June 30, ~~2017, 66%~~2018, 70% of DMG’s consolidated capitated medical revenues were earned through contracts with three health plans.

DMG expects that, going forward, substantially all of its revenue will continue to be derived from its contracts with health plans. Each health plan may immediately terminate any of DMG’s contracts and/or any individual credentialed physician upon the occurrence of certain events. They may also amend the material terms of the contracts under certain circumstances. Failure to maintain the contracts on favorable terms, for any reason, would materially and adversely affect DMG’s results of operations and financial condition. A material decline in the number of members could also have a material adverse effect on DMG’s results of operations.

Notwithstanding each health plan’s and DMG’s current shared interest in providing service to DMG’s members who are enrolled in the subject health plans, the health plans may have different and, at times, opposing economic interests from those of DMG. The health plans provide a wide range of health insurance services across a wide range of geographic regions,

utilizing a vast network of providers. As a result, they and DMG may have different views regarding the proper pricing of services and/or the proper pricing of the various service providers in their provider networks, the cost of which DMG bears to

the extent that the services of such service providers are utilized. These health plans may also have different views than DMG regarding the efforts and expenditures that they, DMG, and/or other service providers should make to achieve and/or maintain various quality ratings. In addition, several health plans have acquired or announced their intent to acquire provider organizations. If health plans with which DMG contracts acquire a significant number of provider organizations, they may not continue to contract with DMG or contract on less favorable terms or seek to prevent DMG from acquiring or entering into arrangements with certain providers. Similarly, as a result of changes in laws, regulations, consumer preferences, or other factors, the health plans may find it in their best interest to provide health insurance services pursuant to another payment or reimbursement structure. In the event DMG’s interests diverge from the interests of the health plans, DMG may have limited recourse or alternative options in light of its dependence on these health plans. There can be no assurances that DMG will continue to find it mutually beneficial to work with these health plans. As a result of various restrictive provisions that appear in some of the managed care agreements with health plans, DMG may at times have limitations on its ability to cancel an agreement with a particular health plan and immediately thereafter contract with a competing health plan with respect to the same service area.

DMG and its associated physicians, physician groups and IPAs and other physicians may be required to continue providing services following termination or renegotiation of certain agreements with health plans.

There are circumstances under federal and state law pursuant to which DMG and its associated physician groups, IPAs and other physicians could be obligated to continue to provide medical services to DMG members in their care following a termination of their applicable risk agreement with health plans and termination of the receipt of payments thereunder. In certain cases, this obligation could require the physician group or IPA to provide care to such member following the bankruptcy or insolvency of a health plan. Accordingly, the obligations to provide medical services to DMG members (and the associated costs) may not terminate at the time the applicable agreement with the health plan terminates, and DMG may not be able to recover its cost of providing those services from the health plan, which could have a material adverse effect on DMG’s business, results of operations and financial condition.

DMG operates primarily in California, Florida, Nevada, New Mexico, Washington and Colorado and may not be able to successfully establish a presence in new geographic regions.

DMG derives substantially all of its revenue from operations in California, Florida, Nevada, New Mexico, Washington and Colorado (which we refer to as the Existing Geographic Regions). As a result, DMG’s exposure to many of the risks described herein is not mitigated by a greater diversification of geographic focus. Furthermore, due to the concentration of DMG’s operations in the Existing Geographic Regions, it may be adversely affected by economic conditions, natural disasters (such as earthquakes or hurricanes), or acts of war or terrorism that disproportionately affect the Existing Geographic Regions as compared to other states and geographic markets.

To expand the operations of its network outside of the Existing Geographic Regions, DMG must devote resources to identify and explore perceived opportunities. Thereafter, DMG must, among other things, recruit and retain qualified personnel, develop new offices, establish potential new relationships with one or more health plans, and establish new relationships with physicians and other healthcare providers. The ability to establish such new relationships may be significantly inhibited by competition for such relationships and personnel in the healthcare marketplace in the targeted new geographic regions. Additionally, DMG may face the risk that a substantial portion of the patients served in a new geographic area may be enrolled in a Medicare FFS program and will not desire to transition to a Medicare Advantage program, such as those offered through the health plans that DMG serves, or they may enroll with other health plans with ~~whom~~which DMG does not contract to receive services, which could reduce substantially DMG’s perceived opportunity in such geographic area. In addition, if DMG were to seek to expand outside of the Existing Geographic Regions, DMG would be required to comply with laws and regulations of states that may differ from the ones in which it currently operates, and could face competitors with greater knowledge of such local markets. DMG anticipates that any geographic expansion may require it to make a substantial investment of management time, capital and/or other resources. There can be no assurance that DMG will be able to establish profitable operations or relationships in any new geographic markets.

Reductions in the quality ratings of the health plans DMG serves could have a material adverse effect on its business, results of operations and financial condition.

As a result of the ACA, the level of reimbursement each health plan receives from CMS is dependent, in part, upon the quality rating of the Medicare plan. Such ratings impact the percentage of any cost savings rebate and any bonuses earned by such health plan. Since a significant portion of DMG’s revenue is expected to be calculated as a percentage of CMS

reimbursements received by these health plans with respect to DMG members, reductions in the quality ratings of a health plan that DMG serves could have a material adverse effect on its business, results of operations and financial condition.

Given each health plan’s control of its plans and the many other providers that serve such plans, DMG believes that it will have limited ability to influence the overall quality rating of any such plan. The BBA passed in February 2018 implements certain changes to prevent artificial inflation of star ratings for Medicare Advantage plans offered by the same organization. In addition, CMS has ~~begun terminating~~terminated plans that have had a rating of less than three stars for three consecutive years, whereas Medicare Advantage plans with five stars are permitted to conduct enrollment throughout almost the entire year. ~~Accordingly, since~~Although CMS’ authority to terminate plans solely for failing to achieve the minimum quality star ratings has been suspended through the end of plan year 2018, low quality ratings can still potentially lead to the termination of a plan that DMG serves, DMG may not be able to prevent the potential termination of a contracting plan or a shift of patients to other plans based upon quality issues which could, in turn, have a material adverse effect on DMG’s business, results of operations and financial condition.

DMG’s records and submissions to a health plan may contain inaccurate or unsupportable information regarding risk adjustment scores of members, which could cause DMG to overstate or understate its revenue and subject it to various penalties.

DMG, on behalf of itself and its associated physicians, physician groups and IPAs, submits to health plans claims and encounter data that support the Medicare Risk Adjustment Factor (RAF) scores attributable to members. These RAF scores determine, in part, the revenue to which the health plans and, in turn, DMG is entitled for the provision of medical care to such members. The data submitted to CMS by each health plan is based, in part, on medical charts and diagnosis codes prepared and submitted by DMG. Each health plan generally relies on DMG and its employed or affiliated physicians to appropriately document and support such RAF data in DMG’s medical records. Each health plan also relies on DMG and its employed or affiliated physicians to appropriately code claims for medical services provided to members. Erroneous claims and erroneous encounter records and submissions could result in inaccurate PMPM fee revenue and risk adjustment payments, which may be subject to correction or retroactive adjustment in later periods. This corrected or adjusted information may be reflected in financial statements for periods subsequent to the period in which the revenue was recorded. DMG might also need to refund a portion of the revenue that it received, which refund, depending on its magnitude, could damage its relationship with the applicable health plan and could have a material adverse effect on DMG’s business, results of operations and financial condition.

In June 2015, we received a subpoena from the OIG requesting information relating to our and our ~~subsidiaries’~~subsidiaries' (including ~~DMG’s~~DMG's and its subsidiary JSA’s) provision of services to Medicare Advantage plans and related patient diagnosis coding and risk adjustment submissions and payments. See ~~“Item 1. Legal Proceedings” in Part II of this report and~~ Note 10 to the condensed consolidated financial statements included in this report for further ~~details.~~details and discussions of legal proceedings elsewhere in these Risk Factors.

Additionally, CMS audits Medicare Advantage plans for documentation to support RAF-related payments for members chosen at random. The Medicare Advantage plans ask providers to submit the underlying documentation for members that they serve. It is possible that claims associated with members with higher RAF scores could be subject to more scrutiny in a CMS or plan audit. There is a possibility that a Medicare Advantage plan may seek repayment from DMG should CMS make any payment adjustments to the Medicare Advantage plan as a result of its audits. The plans also may hold DMG liable for any penalties owed to CMS for inaccurate or unsupportable RAF scores provided by DMG. In addition, DMG could be liable for penalties to the government under the FCA that range from $5,500 to $11,000 (adjusted for inflation) for each false claim, plus up to three times the amount of damages caused by each false claim, which can be as much as the amounts received directly or indirectly from the government for each such false claim. On ~~February 3, 2017,~~January 29, 2018, the DOJ issued a final rule announcing adjustments to FCA penalties, under which the per claim penalty range increases from ~~$10,957~~$11,181 to ~~$21,916~~$22,363 for penalties assessed after ~~February 3, 2017,~~January 29, 2018, so long as the underlying conduct occurred after November 2, 2015.

CMS has indicated that payment adjustments will not be limited to RAF scores for the specific Medicare Advantage enrollees for which errors are found but may also be extrapolated to the entire Medicare Advantage plan subject to a particular CMS contract. CMS has described its audit process as plan-year specific and stated that it will not extrapolate audit results for plan years prior to 2011. Because CMS has not stated otherwise, there is a risk that payment adjustments made as a result of one plan year’s audit would be extrapolated to prior plan years after 2011.

There can be no assurance that a health plan will not be randomly selected or targeted for review by CMS or that the outcome of such a review will not result in a material adjustment in DMG’s revenue and profitability, even if the information DMG submitted to the plan is accurate and supportable.

Separately, as described in further detail in ~~“Item 1. Legal Proceedings” in Part II of this report and~~ Note 10 to the condensed consolidated financial statements included in this report, onin March ~~13,~~ 2015, JSA, a subsidiary of DMG, received a subpoena from the OIG that relates, in part, to risk adjustment practices and data.

See also discussions of legal proceedings elsewhere in these Risk Factors.

A failure to accurately estimate incurred but not reported medical expense could adversely affect DMG’s results of operations.

Patient care costs include estimates of future medical claims that have been incurred by the patient but for which the provider has not yet billed DMG. These claim estimates are made utilizing actuarial methods and are continually evaluated and adjusted by management, based upon DMG’s historical claims experience and other factors, including an independent assessment by a nationally recognized actuarial firm. Adjustments, if necessary, are made to medical claims expense and capitated revenues when the assumptions used to determine DMG’s claims liability ~~changes~~change and when actual claim costs are ultimately determined.

Due to the inherent uncertainties associated with the factors used in these estimates and changes in the patterns and rates of medical utilization, materially different amounts could be reported in DMG’s financial statements for a particular period under different conditions or using different, but still reasonable, assumptions. It is possible that DMG’s estimates of this type of claim may be inadequate in the future. In such event, DMG’s results of operations could be adversely impacted. Further, the inability to estimate these claims accurately may also affect DMG’s ability to take timely corrective actions, further exacerbating the extent of any adverse effect on DMG’s results of operations.

DMG faces certain competitive threats which could reduce DMG’s profitability and increase competition for patients.

DMG faces certain competitive threats based on certain features of the Medicare programs, including the following:

As a result of the direct and indirect impacts of the ACA, many Medicare beneficiaries may decide that an original Medicare FFS program is more attractive than a Medicare Advantage plan. As a result, enrollment in the health plans DMG serves may decrease.

Managed care companies offer alternative products such as regional preferred provider organizations (PPOs) and private FFS plans. Medicare PPOs and private FFS plans allow their patients more flexibility in selecting physicians than Medicare Advantage health plans, which typically require patients to coordinate care with a primary care physician. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 has encouraged the creation of regional PPOs through various incentives, including certain risk corridors, or cost reimbursement provisions, a stabilization fund for incentive payments, and special payments to hospitals not otherwise contracted with a Medicare Advantage plan that treat regional plan enrollees. The formation of regional Medicare PPOs and private FFS plans may affect DMG’s relative attractiveness to existing and potential Medicare patients in their service areas.

The payments for the local and regional Medicare Advantage plans are based on a competitive bidding process that may indirectly cause a decrease in the amount of the PMPM fee or result in an increase in benefits offered.

The annual enrollment process and subsequent lock-in provisions of the ACA may adversely affect DMG’s level of revenue growth as it will limit the ability of a health plan to market to and enroll new Medicare beneficiaries in its established service areas outside of the annual enrollment period.

CMS allows Medicare beneficiaries who are enrolled in a Medicare Advantage plan with a quality rating of 4.5 stars or less to enroll in a 5-star rated Medicare Advantage plan at any time during the benefit year. Therefore, DMG may face a competitive disadvantage in recruiting and retaining Medicare beneficiaries.

In addition to the competitive threats intrinsic to the Medicare programs, competition among health plans and among healthcare providers may also have a negative impact on DMG’s profitability. For example, due to the large population of Medicare beneficiaries, DMG’s Existing Geographic Regions have become increasingly attractive to health plans that may compete with DMG. DMG may not be able to continue to compete profitably in the healthcare industry if additional competitors enter the same market. If DMG cannot compete profitably, the ability of DMG to compete with other service providers that contract with competing health plans may be substantially impaired. Furthermore, if DMG is unable to obtain new members or experiences a loss of existing members to competitors during the open enrollment period for Medicare it could have a material adverse effect on DMG’s business, results of operations and financial condition.

DMG competes directly with various regional and local companies that provide similar services in DMG’s Existing Geographic Regions. DMG’s competitors vary in size and scope and in terms of products and services offered. DMG believes that some of its competitors and potential competitors may be significantly larger than DMG and have greater financial, sales, marketing and other resources. Furthermore, it is DMG’s belief that some of its competitors may make strategic acquisitions or establish cooperative relationships among themselves.

A disruption in DMG’s healthcare provider networks could have a material adverse effect on DMG’s operations and profitability.

In any particular service area, healthcare providers or provider networks could refuse to contract with DMG, demand higher payments, or take other actions that could result in higher healthcare costs, disruption of benefits to DMG’s members, or difficulty in meeting applicable regulatory or accreditation requirements. In some service areas, healthcare providers or provider networks may have significant market positions. If healthcare providers or provider networks refuse to contract with DMG, use their market position to negotiate favorable contracts, or place DMG at a competitive disadvantage, then DMG’s ability to market or to be profitable in those service areas could be adversely affected. DMG’s provider networks could also be disrupted by the financial insolvency of a large provider group. Any disruption in DMG’s provider networks could result in a loss of members or higher healthcare costs.

DMG’s revenues and profits could be diminished if DMG fails to retain and attract the services of key primary care physicians.

Key primary care physicians with large patient enrollment could retire, become disabled, terminate their provider contracts, get lured away by a competing independent physician association or medical group, or otherwise become unable or unwilling to continue practicing medicine or continue contracting with DMG or its associated physicians, physician groups or IPAs. In addition, DMG’s associated physicians, physician groups and IPAs could view the business model as unfavorable or unattractive to such providers, which could cause such associated physicians, physician groups or IPAs to terminate their relationships with DMG. Moreover, given limitations relating to the enforcement of post-termination noncompetition covenants in California, it would be difficult to restrict a primary care physician from competing with DMG’s associated physicians, physician groups or IPAs. As a result, members who have been served by such physicians could choose to enroll with competitors’ physician organizations or could seek medical care elsewhere, which could reduce DMG’s revenues and profits. Moreover, DMG may not be able to attract new physicians to replace the services of terminating physicians or to service its growing membership.

Participation in ACO programs is subject to federal regulation, supervision, and evolving regulatory developments that may result in financial liability.

The ACA established the Medicare Shared Savings Program (MSSP) for ACOs, which took effect in January 2012. Under the MSSP, eligible organizations are accountable for the quality, cost and overall care of Medicare beneficiaries assigned to an ACO and may be eligible to share in any savings below a specified benchmark amount. The Secretary of HHS is also authorized, but not required, to use capitation payment models with ACOs. DMG has formed an MSSP ACO through a subsidiary, which operates in California, Florida, and Nevada and is evaluating whether to participate in more ACOs in the future. The continued development and expansion of ACOs will have an uncertain impact on DMG’s revenue and profitability. DaVita Kidney Care is also participating as a dialysis provider in Arizona, Florida, New Jersey, and Pennsylvania for the Innovation Center’s CEC Model.

The ACO programs are relatively new and therefore operational and regulatory guidance is limited. It is possible that the operations of DMG’s subsidiary ACO may not fully comply with current or future regulations and guidelines applicable to ACOs, may not achieve quality targets or cost savings, or may not attract or retain sufficient physicians or patients to allow DMG to meet its objectives. Additionally, poor performance could put the DMG ACO at financial risk with a potential obligation to CMS. Traditionally, other than fee-for-service billing by the medical clinics and healthcare facilities operated by DMG, DMG has not directly contracted with CMS and has not operated any health plans or provider sponsored networks. Therefore, DMG may not have the necessary experience, systems or compliance to successfully achieve a positive return on its investment in the ACO or to avoid financial or regulatory liability. DMG believes that its historical experience with fully delegated managed care will be applicable to operation of its subsidiary ACO, but there can be no such assurance.

California hospitals may terminate their agreements with HealthCare Partners Affiliates Medical Group and DaVita Health Plan of California, Inc. (formerly HealthCare Partners Plan, Inc., and, together with HealthCare Partners Affiliates Medical Group ~~AMG)~~(AMG)) or reduce the fees they pay to DMG.

In California, AMG maintains significant hospital arrangements designed to facilitate the provision of coordinated hospital care with those services provided to members by AMG and its associated physicians, physician groups and IPAs. Through contractual arrangements with certain key hospitals, AMG provides utilization review, quality assurance and other management services related to the provision of patient care services to members by the contracted hospitals and downstream hospital contractors. In the event that any one of these key hospital agreements is amended in a financially unfavorable manner

or is otherwise terminated, such events could have a material adverse effect on DMG’s business, results of operations and financial condition.

DMG’s professional liability and other insurance coverage may not be adequate to cover DMG’s potential liabilities.

DMG maintains primary professional liability insurance and other insurance coverage through California Medical Group Insurance Company, Risk Retention Group, an Arizona corporation in which DMG is the majority owner, and through excess coverage contracted through third-party insurers. DMG believes such insurance is adequate based on its review of what it believes to be all applicable factors, including industry standards. Nonetheless, potential liabilities may not be covered by insurance, insurers may dispute coverage or may be unable to meet their obligations, the amount of insurance coverage and/or related reserves may be inadequate, or the amount of any DMG self-insured retention may be substantial. There can be no assurances that DMG will be able to obtain insurance coverage in the future, or that insurance will continue to be available on a cost-effective basis, if at all. Moreover, even if claims brought against DMG are unsuccessful or without merit, DMG would have to defend itself against such claims. The defense of any such actions may be time-consuming and costly and may distract DMG management’s attention. As a result, DMG may incur significant expenses and may be unable to effectively operate its business.

Changes in the rates or methods of third-party reimbursements may materially adversely affect ~~DMG~~DMG's business, results of operations and financial condition.

Any negative changes in governmental capitation or FFS rates or methods of reimbursement for the services DMG provides could have a material adverse effect on DMG’s business, results of operations and financial condition. Since governmental healthcare programs generally reimburse on a fee schedule basis rather than on a charge-related basis, DMG generally cannot increase its revenues from these programs by increasing the amount it charges for its services. Moreover, if DMG’s costs increase, DMG may not be able to recover its increased costs from these programs. Government and private payors have taken and may continue to take steps to control the cost, eligibility for, use, and delivery of healthcare services due to budgetary constraints, and cost containment pressures as well as other financial issues. DMG believes that these trends in cost containment will continue. These cost containment measures, and other market changes in non-governmental insurance plans have generally restricted DMG’s ability to recover, or shift to non-governmental payors, any increased costs that DMG experiences. DMG’s business, results of operations and financial condition may be materially adversely affected by these cost containment measures, and other market changes.

DMG’s business model depends on numerous complex management information systems and any failure to successfully maintain these systems or implement new systems could materially harm DMG’s operations and result in potential violations of healthcare laws and regulations.

DMG depends on a complex, specialized, and integrated management information system and standardized procedures for operational and financial information, as well as for DMG’s billing operations. DMG may experience unanticipated delays, complications or expenses in implementing, integrating, and operating these integrated systems. Moreover, DMG may be unable to enhance its existing management information system or implement new management information systems where necessary. DMG’s management information system may require modifications, improvements or replacements that may require both substantial expenditures as well as interruptions in operations. DMG’s ability to implement and operate its integrated systems is subject to the availability of information technology and skilled personnel to assist DMG in creating and maintaining these systems.

DMG’s failure to successfully implement and maintain all of its systems could have a material adverse effect on its business, financial condition and results of operations. For example, DMG’s failure to successfully operate its billing systems could lead to potential violations of healthcare laws and regulations. If DMG is unable to handle its claims volume, or if DMG is unable to pay claims timely, DMG may become subject to a health plan’s corrective action plan or de-delegation until the problem is corrected, and/or termination of the health plan’s agreement with DMG. This could have a material adverse effect on

DMG’s operations and profitability. In addition, if DMG’s claims processing system is unable to process claims accurately, the data DMG uses for its incurred but not reported ~~(IBNR)~~ estimates could be incomplete and DMG’s ability to accurately estimate claims liabilities and establish adequate reserves could be adversely affected. Finally, if DMG’s management information systems are unable to function in compliance with applicable state or federal rules and regulations, including medical information confidentiality laws such as HIPAA, possible penalties and fines due to this lack of compliance could have a material adverse effect on DMG’s financial condition, and results of operations.

DMG may be impacted by eligibility changes to government and private insurance programs.

Due to potential decreased availability of healthcare through private employers, the number of patients who are uninsured or participate in governmental programs may increase. The ACA has increased the participation of individuals in the Medicaid program in states that elected to participate in the expanded Medicaid coverage. A shift in payor mix from managed care and other private payors to government payors as well as an increase in the number of uninsured patients may result in a reduction in the rates of reimbursement to DMG or an increase in uncollectible receivables or uncompensated care, with a corresponding decrease in net revenue. Changes in the eligibility requirements for governmental programs such as the Medicaid program under the ACA and state decisions on whether to participate in the expansion of such programs also could increase the number of patients who participate in such programs and the number of uninsured patients. Even for those patients who remain in private insurance plans, changes to those plans could increase patient financial responsibility, resulting in a greater risk of uncollectible receivables. These factors and events could have a material adverse effect on DMG’s business, results of operations and financial condition.

Negative publicity regarding the managed healthcare industry generally or DMG in particular could adversely affect DMG’s results of operations or business.

Negative publicity regarding the managed healthcare industry generally, the Medicare Advantage program or DMG in particular, may result in increased regulation and legislative review of industry practices that further increase DMG’s costs of doing business and adversely affect DMG’s results of operations or business by:

requiring DMG to change its products and services;

increasing the regulatory, including compliance, burdens under which DMG operates, which, in turn, may negatively impact the manner in which DMG provides services and increase DMG’s costs of providing services;

adversely affecting DMG’s ability to market its products or services through the imposition of further regulatory restrictions regarding the manner in which plans and providers market to Medicare Advantage enrollees; or

adversely affecting DMG’s ability to attract and retain members.

Risk factors related to ownership of our common stock:

Provisions in our charter documents, compensation programs and Delaware law may deter a change of control that our stockholders would otherwise determine to be in their best interests.

Our charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in our management, or limit the ability of our stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting our stockholders from acting by written consent; requiring 90 days advance notice of stockholder proposals or nominations to our Board of Directors (or 120 days for nominations made using proxy access); and granting our Board of Directors the authority to issue preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.

Most of our outstanding employee stock-based compensation awards include a provision accelerating the vesting of the awards in the event of a change of control. We also maintain a change of control protection program for our employees who do not have a significant number of stock awards, which has been in place since 2001, and which provides for cash bonuses to the employees in the event of a change of control. Based on the market price of our common stock and shares outstanding on June 30, ~~2017,~~2018, these cash bonuses would total approximately ~~$488~~$468 million if a change of control transaction occurred at that price and our Board of Directors did not modify this program. These change of control provisions may affect the price an acquirer would be willing to pay for our Company.

We are also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, would prohibit us from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder.

These provisions may discourage, delay or prevent an acquisition of our Company at a price that our stockholders may find attractive. These provisions could also make it more difficult for our stockholders to elect directors and take other corporate actions and could limit the price that investors might be willing to pay for shares of our common stock.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table summarizes the Company’s repurchases of its common stock during the second quarter of ~~2017:~~2018:

Total number
of shares purchased Average
price paid per share Total number
of shares
purchased as
part of publicly
announced plans or programs Approximate
dollar value
of shares that
may yet be
purchased under
the plans
or programs
(in millions)
Period
April 1-30, 2017 —
—
—
677.1
May 1-31, 2017 2,922,760
$ 64.75
2,922,760
487.9
June 1-30, 2017 651,813
65.08
651,813
445.4
Total 3,574,573
$ 64.81
3,574,573



	Total number of shares purchased	Average price paid per share		Total number of shares purchased as part of publicly announced plans or programs	Approximate dollar value of shares that may yet be purchased under the plans or programs (in millions)
Period	Total number of shares purchased	Average price paid per share
April 1-30, 2018	3,970,706	$	63.46	3,970,706	$	568.7
May 1-31, 2018	2,288,507	66.39		2,288,507	416.8
June 1-30, 2018	1,538,499	69.94		1,538,499	309.2
Total	7,797,712	$	65.60	7,797,712

On July ~~13, 2016,~~11, 2018, our Board of Directors approved an additional share ~~repurchases~~repurchase authorization in the amount of approximately ~~$1.2~~$1.39 billion. ~~These~~This share ~~repurchases were~~repurchase authorization was in addition to the approximately ~~$259~~$110 million remaining at that time under our Board of Directors’ prior share repurchase authorization ~~announced~~approved in ~~April 2015.~~October 2017. We are authorized to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, Rule 10b5-1 plans or any combination of the foregoing, depending upon market conditions and other considerations. During the quarter ended June 30, ~~2017,~~2018, we repurchased a total of ~~3,574,573~~7,797,712 shares of our common stock for ~~$232~~approximately $512 million orat an average price of ~~$64.81~~$65.60 per share. As of ~~June 30, 2017,~~July 31, 2018, we ~~have a total of~~had approximately ~~$445~~$1,426 million remaining in ~~outstanding~~ Board authorizations available for share repurchases under our stock repurchase ~~authorizations. We have not repurchased any shares from July 1, 2017 through August 1, 2017.~~program. Although these share repurchase authorizations have no expiration dates, we are subject to share repurchase limitations under the terms of the senior secured credit facilities and the indentures governing our senior notes.

Items 3 4 and 54 are not applicable

Item 5. Other Information

On July 31, 2018, Mr. James Hilger, the Company’s Chief Accounting Officer, and the Company entered into a Transition Agreement relating to Mr. Hilger’s retirement from the Company. Under the Transition Agreement, Mr. Hilger will serve as Chief Accounting Officer until March 31, 2020 (the Retirement Date) or his earlier termination of employment. The period from the effective date of the Transition Agreement through Mr. Hilger’s separation from the Company is referred to as the “Transition Period.”

Under the Transition Agreement, Mr. Hilger will (i) continue to receive his current base salary of $375,000 during the Transition Period, (ii) remain eligible for an annual incentive bonus for the 2018, 2019 and 2020 performance years, with a maximum potential annual bonus of $350,000 and actual payouts determined based on the weighted average bonus generally paid as an annual incentive to the Company’s other employees during the applicable performance year and the 2020 bonus prorated for his service during such performance year, (iii) remain eligible to receive a 2019 annual equity award with a grant date fair value equal to $400,000 and to be delivered through the same equity vehicles and form of equity award agreements as received by Mr. Hilger with respect to his 2018 annual equity award and (iv) subject to Mr. Hilger’s continued employment through the Retirement Date and execution of a release of claims in favor of the Company, receive full vesting of his outstanding restricted stock unit awards (RSUs) and continued vesting of his outstanding stock appreciation rights (SARs) in accordance with the normal vesting schedules applicable to Mr. Hilger’s SAR awards. If Mr. Hilger’s employment with the Company is terminated by the Company other than due to death, disability or cause and Mr. Hilger executes a release in favor of the Company, then Mr. Hilger will receive the following benefits in lieu of any severance Mr. Hilger would receive under his current employment agreement with the Company: (i) salary continuation through the Retirement Date; (ii) bonuses, to the extent unpaid, with respect to 2018, 2019 and 2020, as described above; (iii) if the termination occurs prior to the grant date for the 2019 annual equity awards, a cash payment equal to $400,000 in lieu of a 2019 equity grant; and (iv) full vesting of Mr. Hilger’s outstanding RSUs and continued vesting of Mr. Hilger’s outstanding SARs in accordance with the normal vesting schedules applicable to such SAR awards. Under the terms of the Transition Agreement, Mr. Hilger has agreed to continue to be bound by certain restrictive covenants, including covenants relating to non-competition, non-solicitation and non-disclosure, set forth in his employment agreement and equity award agreements. The foregoing description is a summary of the Transition Agreement and is qualified in its entirety by reference to the Transition Agreement, which is filed as Exhibit 10.5 to this Quarterly Report on Form 10-Q and incorporated herein by reference.

Item 6. Exhibits

(a) Exhibits

The information required by this Item is set forth in the Index to Exhibits that precedes the signature page of this Quarterly Report on Form 10-Q.

INDEX TO EXHIBITS



Exhibit
Number

~~10.1~~ 2.1		~~Employment Agreement, effective April 27, 2016,~~Amendment No. 3, dated as of June 22, 2018, by and ~~between~~among DaVita Inc., HealthCare Partners Holdings, LLC, and ~~Kathleen A. Waters.~~Robert D. Mosher, as the member representative, amending that certain Agreement and Plan of Merger, dated as of May 20, 2012, by and among DaVita Inc., Seismic Acquisition LLC, HealthCare Partners Holdings, LLC, and Robert D. Mosher, as the member representative, as amended by that certain Amendment to Agreement and Plan of Merger, dated as of July 6, 2012, and Amendment No. 2 to Agreement and Plan of Merger, dated as of August 30, 2013. ü

10.1		Form of Stock Appreciation Rights Agreement-Board members (DaVita Inc. 2011 Incentive Award Plan). ü*

10.2		Form of Restricted Stock Units Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan). ü*

10.3		Form of Stock Appreciation Rights Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan). ü*

10.4		Form of Performance Stock Units Agreement -Executives (DaVita Inc. 2011 Incentive Award Plan). ü*

10.5		Transition Agreement, dated as of July 31, 2018, by and between DaVita Inc. and James Hilger. ü*

12.1		Ratio of earnings to fixed charges. ü

31.1		Certification of the Chief Executive Officer, dated ~~August 1, 2017,~~May 3, 2018, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. ü

31.2		Certification of the Chief Financial Officer, dated ~~August 1, 2017,~~May 3, 2018, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. ü

32.1		Certification of the Chief Executive Officer, dated ~~August 1, 2017,~~May 3, 2018, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ü

32.2		Certification of the Chief Financial Officer, dated ~~August 1, 2017,~~May 3, 2018, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ü

101.INS		XBRL Instance Document. ü

101.SCH		XBRL Taxonomy Extension Schema Document. ü

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document. ü

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document. ü

101.LAB		XBRL Taxonomy Extension Label Linkbase Document. ü

101.PRE		XBRL Taxonomy Extension Presentation, Linkbase Document. ü



ü	Filed herewith.
*	~~Portions of this exhibit are subject to a request for confidential treatment and have been redacted and filed separately with the SEC.~~Management contract or executive compensation plan or arrangement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	DAVITA INC.

	BY:		/s/ JAMES K. HILGER
			James K. Hilger
			Chief Accounting Officer*

Date: August 1, ~~2017~~2018



*	Mr. Hilger has signed both on behalf of the Registrant as a duly authorized officer and as the Registrant’s principal accounting officer.

~~INDEX TO EXHIBITS~~



~~Exhibit~~
~~Number~~

~~10.1~~		~~Employment Agreement, effective April 27, 2016, by and between DaVita Inc. and Kathleen A. Waters.~~ ü

~~12.1~~		~~Ratio of earnings to fixed charges.~~ ü

~~31.1~~		~~Certification of the Chief Executive Officer, dated August 1, 2017, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.~~ ü

~~31.2~~		~~Certification of the Chief Financial Officer, dated August 1, 2017, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.~~ ü

~~32.1~~		~~Certification of the Chief Executive Officer, dated August 1, 2017, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.~~ ü

~~32.2~~		~~Certification of the Chief Financial Officer, dated August 1, 2017, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.~~ ü

~~101.INS~~		~~XBRL Instance Document.~~ ü

~~101.SCH~~		~~XBRL Taxonomy Extension Schema Document.~~ ü

~~101.CAL~~		~~XBRL Taxonomy Extension Calculation Linkbase Document.~~ ü

~~101.DEF~~		~~XBRL Taxonomy Extension Definition Linkbase Document.~~ ü

~~101.LAB~~		~~XBRL Taxonomy Extension Label Linkbase Document.~~ ü

~~101.PRE~~		~~XBRL Taxonomy Extension Presentation, Linkbase Document.~~ ü



ü	~~Filed herewith.~~
*	~~Portions of this exhibit are subject to a request for confidential treatment and have been redacted and filed separately with the SEC.~~



Delaware		51-0354549
(State of incorporation)		(I.R.S. Employer Identification No.)



Large accelerated filer	☒	Accelerated filer	☐

Non-accelerated filer	☐ (Do not check if a smaller reporting company)	Smaller reporting company	☐

Emerging growth company	☐



		Page No.
	PART I. FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements:
	Consolidated Statements of Income for the three and six months ended June 30, ~~2017~~2018 and June 30, ~~2016~~2017	1
	Consolidated Statements of Comprehensive Income for the three and six months ended June 30, ~~2017~~2018 and June 30, ~~2016~~2017	2
	Consolidated Balance Sheets as of June 30, ~~2017~~2018 and December 31, ~~2016~~2017	3
	Consolidated Statements of Cash Flows for the six months ended June 30, ~~2017~~2018 and June 30, ~~2016~~2017	4
	Consolidated Statements of Equity for the six months ended June 30, ~~2017~~2018 and for the year ended December 31, ~~2016~~2017	56
	Notes to Condensed Consolidated Financial Statements	67
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3942
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	61	60
Item 4.	Controls and Procedures	62	61

	PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	6462
Item 1A.	Risk Factors	6862
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	93 94
Item 5.	Other Information	95
Item 6.	Exhibits	9596
	Signature	9698



	Three months ended June 30,						Six months ended June 30,
	2018			2017			2018			2017
Dialysis and related lab patient service revenues	$	2,718,403		$	2,494,609		$	5,309,477		$	4,917,395
Provision for uncollectible accounts	(49,406		)	(109,600		)	(23,861		)	(216,658		)
Net dialysis and related lab patient service revenues	2,668,997			2,385,009			5,285,616			4,700,737
Other revenues	217,956			314,390			450,781			629,913
Total revenues	2,886,953			2,699,399			5,736,397			5,330,650
Operating expenses and charges:
Patient care costs and other costs	2,069,089			1,894,664			4,104,674			3,746,709
General and administrative	264,094			262,796			530,623			525,691
Depreciation and amortization	147,079			140,026			289,878			272,910
Equity investment (income) loss	(9,795		)	825			(9,950		)	148
Provision for uncollectible accounts	(2,100		)	(606		)	(8,100		)	1,304
Investment and other asset impairments	11,245			—			11,245			15,168
Goodwill impairment charges	3,106			10,498			3,106			34,696
Gain on changes in ownership interests, net	(33,957		)	—			(33,957		)	(6,273		)
Gain on settlement, net	—			—			—			(526,827		)
Total operating expenses and charges	2,448,761			2,308,203			4,887,519			4,063,526
Operating income	438,192			391,196			848,878			1,267,124
Debt expense	(119,692		)	(107,934		)	(233,208		)	(212,331		)
Other income, net	1,994			4,798			6,576			8,784
Income from continuing operations before income taxes	320,494			288,060			622,246			1,063,577
Income tax expense	83,868			101,915			154,605			383,580
Net income from continuing operations	236,626			186,145			467,641			679,997
Net income (loss) from discontinued operations, net of tax	69,696			(24,520		)	63,910			(18,087		)
Net income	306,322			161,625			531,551			661,910
Less: Net income attributable to noncontrolling interests	(39,046		)	(34,624		)	(85,589		)	(87,212		)
Net income attributable to DaVita Inc.	$	267,276		$	127,001		$	445,962		$	574,698
Earnings per share:
Basic net income from continuing operations per share attributable to DaVita Inc.	$	1.16		$	0.79		$	2.23		$	3.09
Basic net income per share attributable to DaVita Inc.	$	1.56		$	0.66		$	2.54		$	3.00
Diluted net income from continuing operations per share attributable to DaVita Inc.	$	1.15		$	0.78		$	2.19		$	3.04
Diluted net income per share attributable to DaVita Inc.	$	1.53		$	0.65		$	2.51		$	2.95
Weighted average shares for earnings per share:
Basic	171,617,238			191,088,216			175,267,270			191,728,913
Diluted	174,105,884			193,987,983			177,949,934			194,630,936
Amounts attributable to DaVita Inc.:
Net income from continuing operations	$	199,603		$	151,292		$	390,618		$	592,197
Net income (loss) from discontinued operations	67,673			(24,291		)	55,344			(17,499		)
Net income attributable to DaVita Inc.	$	267,276		$	127,001		$	445,962		$	574,698



	Three months ended June 30,						Six months ended June 30,
	2017			2016			2017			2016
Patient service revenues	$	2,682,467		$	2,583,514		$	5,283,845		$	5,065,448
Less: Provision for uncollectible accounts	(115,485		)	(111,428		)	(228,468		)	(220,633		)
Net patient service revenues	2,566,982			2,472,086			5,055,377			4,844,815
Capitated revenues	1,022,078			899,985			1,940,114			1,787,993
Other revenues	288,417			345,580			579,269			665,979
Total net revenues	3,877,477			3,717,651			7,574,760			7,298,787
Operating expenses and charges:
Patient care costs and other costs	2,859,911			2,671,025			5,582,731			5,253,358
General and administrative	382,315			386,895			774,095			773,324
Depreciation and amortization	200,038			180,381			390,244			349,736
Provision for uncollectible accounts	(606		)	3,566			1,304			6,083
Equity investment (income) loss	(3,614		)	505			(7,549		)	(882		)
Goodwill and asset impairment charges	61,117			176,000			100,483			253,000
Gain on changes in ownership interests, net	—			(29,791		)	(6,273		)	(29,791		)
Gain on settlement, net	—			—			(526,827		)	—
Total operating expenses and charges	3,499,161			3,388,581			6,308,208			6,604,828
Operating income	378,316			329,070			1,266,552			693,959
Debt expense	(107,962		)	(102,894		)	(212,391		)	(205,778		)
Other income, net	5,253			3,215			9,496			6,191
Income before income taxes	275,607			229,391			1,063,657			494,372
Income tax expense	113,982			134,888			401,747			261,710
Net income	161,625			94,503			661,910			232,662
Less: Net income attributable to noncontrolling interests	(34,624		)	(41,121		)	(87,212		)	(81,846		)
Net income attributable to DaVita Inc.	$	127,001		$	53,382		$	574,698		$	150,816
Earnings per share:
Basic net income per share attributable to DaVita Inc.	$	0.66		$	0.26		$	3.00		$	0.74
Diluted net income per share attributable to DaVita Inc.	$	0.65		$	0.26		$	2.95		$	0.73
Weighted average shares for earnings per share:
Basic	191,088,216			204,497,970			191,728,913			204,432,315
Diluted	193,987,983			208,047,172			194,630,936			207,987,530


	June 30, 2017			December 31, 2016			June 30, 2018			December 31, 2017
ASSETS
Cash and cash equivalents	$	711,997		$	913,187		$	389,264		$	508,234
Restricted cash and equivalents							90,884			10,686
Short-term investments	211,436			310,198			4,528			32,830
Accounts receivable, less allowance of $240,918 and $252,056	2,053,812			1,917,302
Accounts receivable, net							1,842,108			1,714,750
Inventories	199,304			164,858			112,729			181,799
Other receivables	644,755			453,483			471,802			372,919
Income tax receivable							23,540			49,440
Prepaid and other current assets	202,464			210,604			97,426			112,058
Income taxes receivable	—			10,596
Current assets held for sale							6,053,081			5,761,642
Total current assets	4,023,768			3,980,228			9,085,362			8,744,358
Property and equipment, net of accumulated depreciation of $3,130,797 and $2,832,160	3,248,030			3,175,367
Intangible assets, net of accumulated amortization of $1,035,664 and $940,731	1,462,894			1,527,767
Property and equipment, net of accumulated depreciation of $3,328,176 and $3,103,662							3,229,098			3,149,213
Intangible assets, net of accumulated amortization of $362,054 and $356,774							100,255			113,827
Equity method and other investments	542,468			502,389			249,020			245,534
Long-term investments	114,693			103,679			34,200			37,695
Other long-term assets	60,140			44,510			59,070			47,287
Goodwill	9,889,791			9,407,317			6,678,559			6,610,279
	$	19,341,784		$	18,741,257		$	19,435,564		$	18,948,193
LIABILITIES AND EQUITY
Accounts payable	$	439,741		$	522,415		$	542,272		$	509,116
Other liabilities	885,274			856,847			568,536			552,662
Accrued compensation and benefits	760,284			815,761			633,092			616,116
Medical payables	390,387			336,381
Current portion of long-term debt	182,323			165,041			1,768,514			178,213
Income tax payable	115,316			—
Current liabilities held for sale							1,271,364			1,185,070
Total current liabilities	2,773,325			2,696,445			4,783,778			3,041,177
Long-term debt	8,910,814			8,947,327			8,175,573			9,158,018
Other long-term liabilities	520,886			465,358			418,123			365,325
Deferred income taxes	855,159			809,128			526,425			486,247
Total liabilities	13,060,184			12,918,258			13,903,899			13,050,767
Commitments and contingencies:
Noncontrolling interests subject to put provisions	1,009,704			973,258			1,047,158			1,011,360
Equity:
Preferred stock ($0.001 par value, 5,000,000 shares authorized; none issued)
Common stock ($0.001 par value, 450,000,000 shares authorized; 194,774,810 and 194,554,491 shares issued and 191,200,237 and 194,554,491 shares outstanding, respectively)	195			195
Common stock ($0.001 par value, 450,000,000 shares authorized; 182,815,212 and 182,462,278 shares issued and 170,820,196 and 182,462,278 shares outstanding, respectively)							183			182
Additional paid-in capital	1,058,090			1,027,182			1,022,783			1,042,899
Retained earnings	4,285,011			3,710,313			4,088,043			3,633,713
Treasury stock (3,574,573 shares at June 30, 2017)	(231,674		)	—
Accumulated other comprehensive loss	(27,308		)	(89,643		)
Total DaVita Inc. shareholders’ equity	5,084,314			4,648,047
Treasury stock (11,995,016 and zero shares, respectively)							(809,900		)	—
Accumulated other comprehensive (loss) income							(21,925		)	13,235
Total DaVita Inc. shareholders' equity							4,279,184			4,690,029
Noncontrolling interests not subject to put provisions	187,582			201,694			205,323			196,037
Total equity	5,271,896			4,849,741			4,484,507			4,886,066
	$	19,341,784		$	18,741,257		$	19,435,564		$	18,948,193


	Six months ended June 30,						Six months ended June 30,
	2017			2016			2018			2017
Cash flows from operating activities:
Net income	$	661,910		$	232,662		$	531,551		$	661,910
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	390,244			349,736			289,878			390,244
Goodwill and asset impairment charges	100,483			253,000
Impairment charges							14,351			100,483
Stock-based compensation expense	17,504			23,717			19,861			17,504
Deferred income taxes	40,938			19,952			56,882			40,938
Equity investment income, net	9,367			14,275			(434		)	9,367
Gain on sales of business interests, net	(6,273		)	(29,791		)	(59,053		)	(6,273		)
Other non-cash charges	28,615			23,120
Changes in operating assets and liabilities, other than from acquisitions and divestitures:
Other non-cash charges, net							44,337			28,611
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:
Accounts receivable	(113,208		)	(104,005		)	(101,746		)	(113,208		)
Inventories	(31,067		)	(9,213		)	71,632			(31,067		)
Other receivables and other current assets	(112,469		)	(107,610		)	(91,685		)	(108,852		)
Other long-term assets	(12,124		)	(431		)	3,454			(12,124		)
Accounts payable	(55,897		)	22,809			35,228			(55,897		)
Accrued compensation and benefits	(63,727		)	41,098			23,818			(63,727		)
Other current liabilities	13,991			112,825			58,321			13,991
Income taxes	123,637			135,026			24,356			123,637
Other long-term liabilities	19,520			(31,531		)	3,824			19,520
Net cash provided by operating activities	1,011,444			945,639			924,575			1,015,057
Cash flows from investing activities:
Additions of property and equipment	(398,940		)	(358,627		)	(473,977		)	(398,940		)
Acquisitions	(619,839		)	(473,314		)	(89,465		)	(619,839		)
Proceeds from asset and business sales	70,236			17,393			116,241			70,236
Purchase of investments available for sale	(6,812		)	(7,873		)	(4,195		)	(6,812		)
Purchase of investments held-to-maturity	(220,632		)	(518,965		)	(3,726		)	(220,591		)
Proceeds from sale of investments available for sale	5,049			5,337			5,662			5,049
Proceeds from investments held-to-maturity	320,484			545,685			32,628			320,484
Purchase of equity investments	(1,194		)	(8,785		)	(10,241		)	(1,194		)
Proceeds from sale of equity investments	—			40,920
Distributions received on equity investments							3,009			—
Net cash used in investing activities	(851,648		)	(758,229		)	(424,064		)	(851,607		)
Cash flows from financing activities:
Borrowings	25,529,555			26,134,952
Payments on long-term debt and other financing costs	(25,593,587		)	(26,196,373		)
Purchase of treasury stock	(231,674		)	(274,926		)
Distributions to noncontrolling interests	(116,075		)	(94,153		)
Stock award exercises and other share issuances, net	8,163			9,465
Contributions from noncontrolling interests	39,872			13,117
Purchase of noncontrolling interests	(1,432		)	(6,240		)
Other	—			10,604
Net cash used in financing activities	(365,178		)	(403,554		)
Effect of exchange rate changes on cash and cash equivalents	4,192			444
Net decrease in cash and cash equivalents	(201,190		)	(215,700		)
Cash and cash equivalents at beginning of the year	913,187			1,499,116
Cash and cash equivalents at end of the period	$	711,997		$	1,283,416


	Non- controlling interests subject to put provisions			DaVita Inc. Shareholders’ Equity																											Non- controlling interests not subject to put provisions			Non- controlling interests subject to put provisions				DaVita Inc. Shareholders’ Equity																										Non- controlling interests not subject to put provisions
									Additional paid-in capital														Accumulated other comprehensive loss																					Additional paid-in capital														Accumulated other comprehensive (loss) income
				Common stock								Retained earnings				Treasury stock																					Common stock										Retained earnings				Treasury stock
				Shares		Amount						Retained earnings			Shares			Amount				Accumulated other comprehensive loss				Total			Shares									Amount					Shares				Retained earnings				Amount			Accumulated other comprehensive (loss) income			Total
Balance at December 31, 2015	$	864,066		217,120		$	217				$	1,118,326			$	4,356,835			(7,366	)				$	(544,772	)		$	(59,826	)			$	213,392
Comprehensive income:
Net income	99,834												879,874															879,874				53,374
Other comprehensive loss																							(29,817		)		(29,817		)		190
Stock purchase shares issued				438		1			23,902								—										23,903
Stock unit shares issued				4		—			(19,815		)						276			19,815							—
Stock-settled SAR shares issued				218		—			(36,685		)						513			36,685							—
Stock-settled stock-based compensation expense									37,970																		37,970
Excess tax benefits from stock awards exercised									13,251																		13,251
Changes in noncontrolling interest from:
Distributions	(111,092		)																												(81,309		)
Contributions	33,517																														14,073
Acquisitions and divestitures	28,874								3,423																		3,423			��	2,585
Partial purchases	(6,660		)						(13,105		)																(13,105		)		(1,747		)
Fair value	65,855								(65,855		)																(65,855		)
Reclassifications and expirations of puts	(1,136		)																												1,136
Purchase of treasury stock																	(16,649	)		(1,072,377		)					(1,072,377		)
Retirement of treasury stock				(23,226	)	(23		)	(34,230		)		(1,526,396		)		23,226			1,560,649							—
Balance at December 31, 2016	$	973,258		194,554		$	195		$	1,027,182			$	3,710,313			—			$	—		$	(89,643	)		$	4,648,047			$	201,694
December 31, 2016																																		$	973,258			194,554		$	195				$	1,027,182			$	3,710,313			—					$	—		$	(89,643	)	$	4,648,047		$	201,694
Comprehensive income:
Net income	56,721												574,698														574,698				30,491			103,641														663,618													663,618			63,296
Other comprehensive income																							62,335				62,335				(2		)																									102,878			102,878			(2		)
Stock purchase shares issued																																						360						22,131																	22,131
Stock unit shares issued				105		—			—								—			—							—											117						(101		)															(101		)
Stock-settled SAR shares issued				116		—			—								—			—							—											398						—																	—
Stock-settled stock-based compensation expense									17,468																		17,468																	34,981																	34,981
Changes in noncontrolling interest from:
Distributions	(72,636		)						—																		—				(43,439		)	(128,853		)																												(82,614		)
Contributions	31,368								—																		—				8,504			52,911																														21,641
Acquisitions and divestitures	34,365								(709		)																(709		)		(7,457		)	43,799										(823		)															(823		)	(5,770		)
Partial purchases	(1,544		)						195																		195				(83		)	(397		)								(2,752		)															(2,752		)	(2,208		)
Fair value	(13,954		)						13,954																		13,954
Reclassifications and expirations of puts	2,126																														(2,126		)
Fair value remeasurements																																		(32,999		)								32,999																	32,999
Purchase of treasury stock																	(3,575	)		(231,674		)					(231,674		)																							(12,967	)	(810,949		)					(810,949		)
Balance at June 30, 2017	$	1,009,704		194,775		$	195		$	1,058,090			$	4,285,011			(3,575	)		$	(231,674	)	$	(27,308	)		$	5,084,314			$	187,582
Retirement of treasury stock																																						(12,967	)	(13		)		(70,718		)		(740,218		)		12,967		810,949							—
Balance at December 31, 2017																																		$	1,011,360			182,462		$	182			$	1,042,899			$	3,633,713			—		$	—			$	13,235		$	4,690,029		$	196,037
Cumulative effect of change in accounting principle																																																8,368										(8,368		)	—
Comprehensive income:
Net income																																		52,278														445,962													445,962			33,311
Other comprehensive loss																																																										(26,792		)	(26,792		)
Stock unit shares issued																																						146						(448		)															(448		)
Stock-settled SAR shares issued																																						207		1				(4,886		)															(4,885		)
Stock-settled stock-based compensation expense																																												19,832																	19,832
Changes in noncontrolling interest from:
Distributions																																		(57,997		)																												(36,009		)
Contributions																																		19,176																														12,393
Acquisitions and divestitures																																		665										79																	79			(203		)
Partial purchases																																		(820		)								(12,197		)															(12,197		)	(206		)
Fair value remeasurements																																		22,496										(22,496		)															(22,496		)
Purchase of treasury stock																																																				(11,995	)	(809,900		)					(809,900		)
Balance at June 30, 2018																																		$	1,047,158			182,815		$	183			$	1,022,783			$	4,088,043			(11,995	)	$	(809,900	)		$	(21,925	)	$	4,279,184		$	205,323



	For the three months ended
	June 30, 2018									June 30, 2017⁽¹⁾
	U.S. dialysis and related lab services			Other - Ancillary services and strategic initiatives			Consolidated			U.S. dialysis and related lab services			Other - Ancillary services and strategic initiatives			Consolidated
Patient service revenues:
Medicare and Medicare Advantage	$	1,526,066		$			$	1,526,066		$	1,313,504		$			$	1,313,504
Medicaid and Managed Medicaid	150,288						150,288			151,286						151,286
Other government	110,338			86,530			196,868			90,712			62,604			153,316
Commercial	796,732			19,139			815,871			764,864			15,324			780,188
Other revenues:
Medicare and Medicare Advantage				154,028			154,028						225,511			225,511
Medicaid and Managed Medicaid				16,158			16,158						19,020			19,020
Commercial				17,006			17,006						26,812			26,812
Other⁽²⁾	4,919			35,034			39,953			4,849			44,322			49,171
Eliminations of intersegment revenues	(20,096		)	(9,189		)	(29,285		)	(13,285		)	(6,124		)	(19,409		)
Total	$	2,568,247		$	318,706		$	2,886,953		$	2,311,930		$	387,469		$	2,699,399


(1)	As noted above, prior period amounts have not been adjusted under the cumulative effect method. The Company's dialysis and related lab services revenues for the three months ended June 30, 2017 has been presented net of the provision for uncollectible accounts of $109,600 in this table to conform to the current period presentation.


(2)	Other consists of management fees and revenue from the Company's ancillary services and strategic initiatives.



	For the six months ended
	June 30, 2018									June 30, 2017⁽¹⁾
	U.S. dialysis and related lab services			Other - Ancillary services and strategic initiatives			Consolidated			U.S. dialysis and related lab services			Other - Ancillary services and strategic initiatives			Consolidated
Patient service revenues:
Medicare and Medicare Advantage	$	3,011,258		$			$	3,011,258		$	2,586,100		$			$	2,586,100
Medicaid and Managed Medicaid	307,783						307,783			295,871						295,871
Other government	217,458			169,068			386,526			182,704			110,366			293,070
Commercial	1,579,711			38,857			1,618,568			1,521,574			29,206			1,550,780
Other revenues:
Medicare and Medicare Advantage				296,786			296,786						450,713			450,713
Medicaid and Managed Medicaid				31,949			31,949						37,615			37,615
Commercial				57,427			57,427						52,020			52,020
Other⁽²⁾	10,033			73,973			84,006			10,159			91,899			102,058
Eliminations of intersegment revenues	(38,519		)	(19,387		)	(57,906		)	(25,084		)	(12,493		)	(37,577		)
Total	$	5,087,724		$	648,673		$	5,736,397		$	4,571,324		$	759,326		$	5,330,650


(1)	Shares associated with stock-settled stock appreciation rights ~~that are~~ excluded from the diluted denominator calculation because they are ~~anti-dilutive~~antidilutive under the treasury stock method.


4.5.	~~Investments in debt~~Short-term and ~~equity securities~~long-term investments


	June 30, 2017						December 31, 2016						June 30, 2018						December 31, 2017
	Held to maturity		Available for sale		Total		Held to maturity		Available for sale		Total		Debt securities		Equity securities		Total		Debt securities		Equity securities		Total
Certificates of deposit, commercial paper and money market funds due within one year	$	210,236	$	—	$	210,236	$	256,827	$	—	$	256,827
Certificates of deposit and other time deposits													$	2,228	$	—	$	2,228	$	31,630	$	—	$	31,630
Investments in mutual funds and common stock	—		53,209		53,209		50,000		47,404		97,404		—		36,500		36,500		—		38,895		38,895
Cash surrender value of life insurance policies	—		62,684		62,684		—		59,646		59,646
	$	210,236	$	115,893	$	326,129	$	306,827	$	107,050	$	413,877	$	2,228	$	36,500	$	38,728	$	31,630	$	38,895	$	70,525
Short-term investments	$	210,236	$	1,200	$	211,436	$	306,827	$	3,371	$	310,198	$	2,228	$	2,300	$	4,528	$	31,630	$	1,200	$	32,830
Long-term investments	—		114,693		114,693		—		103,679		103,679		—		34,200		34,200		—		37,695		37,695
	$	210,236	$	115,893	$	326,129	$	306,827	$	107,050	$	413,877	$	2,228	$	36,500	$	38,728	$	31,630	$	38,895	$	70,525


2.	Revenue recognition


3.4.	~~Accounts receivable~~Restricted cash and equivalents


6.7.	Goodwill



	Goodwill balance as of June 30, 2017		Carrying amount coverage⁽¹⁾		Sensitivities
					Operating income⁽²⁾		Discount rate⁽³⁾
Reporting unit					Operating income⁽²⁾		Discount rate⁽³⁾
DMG Nevada	$	275,914	17.0	%	(2.4	)%	(3.8	)%
DMG Florida	$	397,127	—	%	(1.6	)%	(2.8	)%
DMG New Mexico	$	70,253	—	%	(1.6	)%	(2.4	)%
DMG Washington	$	247,552	9.3	%	(1.7	)%	(3.6	)%


	U.S. dialysis and related lab services			DMG			Other-ancillary services and strategic initiatives			Consolidated total			U.S. dialysis and related lab services			Other-ancillary services and strategic initiatives			Consolidated total
Balance at January 1, 2016	$	5,629,183		$	3,398,264		$	267,032		$	9,294,479
Balance at January 1, 2017													$	5,691,587		$	323,788		$	6,015,375
Acquisitions	75,295			248,901			123,632			447,828			485,434			131,598			617,032
Divestitures	(12,891		)	(2,223		)	(29,645		)	(44,759		)	(32,260		)	(126		)	(32,386		)
Goodwill impairment charges	—			(253,000		)	(28,415		)	(281,415		)	—			(36,196		)	(36,196		)
Foreign currency and other adjustments	—			—			(8,816		)	(8,816		)	—			46,454			46,454
Balance at December 31, 2016	$	5,691,587		$	3,391,942		$	323,788		$	9,407,317
Balance at December 31, 2017													$	6,144,761		$	465,518		$	6,610,279
Acquisitions	427,299			31,796			113,669			572,764			6,357			99,863			106,220
Divestitures	(32,260		)	(29		)	(54		)	(32,343		)	(218		)	(15,166		)	(15,384		)
Goodwill impairment charges	—			(50,619		)	(34,696		)	(85,315		)	—			(3,106		)	(3,106		)
Foreign currency and other adjustments	—			—			27,368			27,368			—			(19,450		)	(19,450		)
Balance at June 30, 2017	$	6,086,626		$	3,373,090		$	430,075		$	9,889,791
Balance at June 30, 2018													$	6,150,900		$	527,659		$	6,678,559

Balance at June 30, 2017:
Balance at June 30, 2018:
Goodwill	$	6,086,626		$	3,865,478		$	499,095		$	10,451,199		$	6,150,900		$	561,937		$	6,712,837
Accumulated impairment charges	—			(492,388		)	(69,020		)	(561,408		)	—			(34,278		)	(34,278		)
	$	6,086,626		$	3,373,090		$	430,075		$	9,889,791		$	6,150,900		$	527,659		$	6,678,559


~~(1)~~	~~Excess of estimated fair value of the reporting unit over its carrying amount as of the latest assessment date.~~


~~(2)~~	~~Potential impact on estimated fair value of a sustained, long-term reduction of 3% in operating income as of the latest assessment date.~~


~~(3)~~	~~Potential impact on estimated fair value of an increase in discount rates of 100 basis points as of the latest assessment date.~~



	June 30, 2018			December 31, 2017
Senior secured credit facilities:
Term Loan A	$	725,000		$	775,000
Term Loan A-2	952,000			—
Term Loan B	3,360,000			3,377,500
Revolver	—			300,000
Senior notes	4,500,000			4,500,000
Acquisition obligations and other notes payable	172,692			150,512
Capital lease obligations	292,296			297,170
Total debt principal outstanding	10,001,988			9,400,182
Discount and deferred financing costs	(57,901		)	(63,951		)
	9,944,087			9,336,231
Less current portion	(1,768,514		)	(178,213		)
	$	8,175,573		$	9,158,018



	Six months ended
	June 30, 2017
Healthcare costs payable, beginning of the period	$	214,275
Add: Components of incurred health care costs
Current year	991,818
Prior years	(6,838		)
Total incurred health care costs	984,980
Less: Claims paid
Current year	727,814
Prior years	186,623
Total claims paid	914,437
Healthcare costs payable, end of the period	$	284,818


2017 (remainder of the year)	96,454
2018	172,318
2018 (remainder of the year)		95,011
2019	746,464	1,712,246
2020	71,432	74,792
2021	3,303,146	3,311,046
2022	1,280,031	1,287,741
2023		162,580
Thereafter	3,495,169	3,358,572


	Amount of losses recognized in OCI on interest rate cap and swap agreements												Location of losses reclassified from accumulated OCI into income		Amount of losses reclassified from accumulated OCI into income															Amount of unrecognized gains (losses) in OCI on interest rate cap agreements																Location of losses reclassified from accumulated OCI into income		Amount of losses reclassified from accumulated OCI into income
	Three months ended June 30,						Six months ended June 30,							Three months ended June 30,								Six months ended June 30,							Three months ended June 30,								Six months ended June 30,										Three months ended June 30,								Six months ended June 30,
Derivatives designated as cash flow hedges	2017			2016			2017			2016				2017				2016				2017				2016			2018				2017				2018				2017						2018				2017				2018				2017
Interest rate swap agreements	$	—		$	(168	)	$	—		$	(860	)		Debt expense		$	—			$	123			$	—			$	274
Interest rate cap agreements	(2,969		)	(4,115		)	(8,186		)	(12,374		)		Debt expense		2,070				610				4,139				1,220			$	(361	)		$	(2,969	)		$	1,053			$	(8,186	)		Debt expense		$	2,070			$	2,070			$	4,140			$	4,139
Tax benefit	1,154			1,667			3,184			5,149			Tax expense		(805		)		(285		)		(1,610		)		(581		)
Tax benefit (expense)																														93				1,154				(271		)		3,184				Tax expense		(533		)		(805		)		(1,066		)		(1,610		)
Total	$	(1,815	)	$	(2,616	)	$	(5,002	)	$	(8,085	)			$	1,265			$	448			$	2,529			$	913		$	(268	)		$	(1,815	)		$	782			$	(5,002	)				$	1,537			$	1,265			$	3,074			$	2,529


	For the three months ended June 30, 2017												For the six months ended June 30, 2017												For the three months ended June 30, 2018										For the six months ended June 30, 2018
	Interest rate cap agreements			Investment securities			Foreign currency translation adjustments			Accumulated other comprehensive (loss) income			Interest rate cap agreements			Investment securities			Foreign currency translation adjustments			Accumulated other comprehensive (loss) income			Interest rate cap agreements			Investment securities	Foreign currency translation adjustments			Accumulated other comprehensive income (loss)			Interest rate cap agreements			Investment securities			Foreign currency translation adjustments			Accumulated other comprehensive income (loss)
Beginning balance	$	(13,952	)	$	3,594		$	(66,528	)	$	(76,886	)	$	(12,029	)	$	2,175		$	(79,789	)	$	(89,643	)	$	(12,527	)		$	39,862		$	27,335		$	(12,408	)	$	5,662		$	19,981		$	13,235
Cumulative effect of change in accounting principle⁽¹⁾																									—				—			—			(2,706		)	(5,662		)	—			(8,368		)
Unrealized (losses) gains	(2,969		)	1,446			49,142			47,619			(8,186		)	3,428			62,403			57,645			(361		)		(50,529		)	(50,890		)	1,053			—			(30,648		)	(29,595		)
Related income tax benefit (expense)	1,154			(389		)	—			765			3,184			(812		)	—			2,372			93				—			93			(271		)	—			—			(271		)
	(1,815		)	1,057			49,142			48,384			(5,002		)	2,616			62,403			60,017			(268		)		(50,529		)	(50,797		)	782			—			(30,648		)	(29,866		)
Reclassification from accumulated other comprehensive income into net income	2,070			(117		)	—			1,953			4,139			(346		)	—			3,793			2,070				—			2,070			4,140			—			—			4,140
Related income tax (expense) benefit	(805		)	46			—			(759		)	(1,610		)	135			—			(1,475		)
Related income tax benefit (expense)																									(533		)		—			(533		)	(1,066		)	—			—			(1,066		)
	1,265			(71		)	—			1,194			2,529			(211		)	—			2,318			1,537				—			1,537			3,074			—			—			3,074
Ending balance	$	(14,502	)	$	4,580		$	(17,386	)	$	(27,308	)	$	(14,502	)	$	4,580		$	(17,386	)	$	(27,308	)	$	(11,258	)		$	(10,667	)	$	(21,925	)	$	(11,258	)	$	—		$	(10,667	)	$	(21,925	)


(1)	Reflects the cumulative effect of a change in accounting principle for ASUs 2016-01 and 2018-03 on classification and measurement of financial instruments and ASU 2018-02 on remeasurement and reclassification of deferred tax effects in accumulated other comprehensive income associated with the 2017 Tax Act.


	For the three months ended June 30, 2016												For the six months ended June 30, 2016												For the three months ended June 30, 2017												For the six months ended June 30, 2017
	Interest rate cap and swap agreements			Investment securities			Foreign currency translation adjustments			Accumulated other comprehensive (loss) income			Interest rate cap and swap agreements			Investment securities			Foreign currency translation adjustments			Accumulated other comprehensive (loss) income			Interest rate cap agreements			Investment securities			Foreign currency translation adjustments			Accumulated other comprehensive (loss) income			Interest rate cap and swap agreements			Investment securities			Foreign currency translation adjustments			Accumulated other comprehensive (loss) income
Beginning balance	$	(15,929	)	$	1,497		$	(39,081	)	$	(53,513	)	$	(10,925	)	$	1,361		$	(50,262	)	$	(59,826	)	$	(13,952	)	$	3,594		$	(66,528	)	$	(76,886	)	$	(12,029	)	$	2,175		$	(79,789	)	$	(89,643	)
Unrealized (losses) gains	(4,283		)	782			(4,844		)	(8,345		)	(13,234		)	1,124			6,337			(5,773		)	(2,969		)	1,446			49,142			47,619			(8,186		)	3,428			62,403			57,645
Related income tax benefit (expense)	1,667			(293		)	—			1,374			5,149			(406		)	—			4,743			1,154			(389		)	—			765			3,184			(812		)	—			2,372
	(2,616		)	489			(4,844		)	(6,971		)	(8,085		)	718			6,337			(1,030		)	(1,815		)	1,057			49,142			48,384			(5,002		)	2,616			62,403			60,017
Reclassification from accumulated other comprehensive income into net income	733			—			—			733			1,494			(152		)	—			1,342			2,070			(117		)	—			1,953			4,139			(346		)	—			3,793
Related income tax (expense) benefit	(285		)	—			—			(285		)	(581		)	59			—			(522		)	(805		)	46			—			(759		)	(1,610		)	135			—			(1,475		)
	448			—			—			448			913			(93		)	—			820			1,265			(71		)	—			1,194			2,529			(211		)	—			2,318
Ending balance	$	(18,097	)	$	1,986		$	(43,925	)	$	(60,036	)	$	(18,097	)	$	1,986		$	(43,925	)	$	(60,036	)	$	(14,502	)	$	4,580		$	(17,386	)	$	(27,308	)	$	(14,502	)	$	4,580		$	(17,386	)	$	(27,308	)



Current assets	$	24,529
Property and equipment	36,295
Amortizable intangible and other long-term assets	11,547
Goodwill	296,582
Current liabilities	(6,912		)
Long-term liabilities	(478		)
	$	361,563



Current assets	$	7,439
Property and equipment	13,278
Amortizable intangible and other long-term assets	14,180
Non-amortizable intangibles	4,833
Goodwill	276,182
Current liabilities	(6,467		)
Long-term liabilities	(2,484		)
Noncontrolling interests	(36,075		)
	$	270,886



Current assets	$	8,854
Property and equipment	4,303
Intangible and other long-term assets	1,486
Goodwill	106,220
Current liabilities	(10,290		)
Long-term liabilities	(171		)
Noncontrolling interests	(1,349		)
	$	109,053



	For the six months ended June 30, 2018
Beginning balance	$	6,388
Contingent earn-out obligations associated with acquisitions	1,436
Remeasurement of fair value for contingent earn-out obligations	(335		)
Ending balance	$	7,489



Beginning balance, January 1, 2017	$	9,977
Contingent earn-out obligations associated with acquisitions	3,849
Remeasurement of fair value for contingent earn-out obligations	415
Payments on contingent earn-out obligations	(2,567		)
	$	11,674


	Total		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Investments in mutual funds and common stock	$	53,209	$	53,209	$	—	$	—	$	36,500	$	36,500	$	—	$	—
Cash surrender value of life insurance policies	$	62,684	$	—	$	62,684	$	—
Interest rate cap agreements	$	1,743	$	—	$	1,743	$	—	$	2,085	$	—	$	2,085	$	—
Funds on deposit with third parties	$	75,671	$	75,671	$	—	$	—
Liabilities
Contingent earn-out obligations	$	11,674	$	—	$	—	$	11,674	$	7,489	$	—	$	—	$	7,489
Temporary equity
Noncontrolling interests subject to put provisions	$	1,009,704	$	—	$	—	$	1,009,704	$	1,047,158	$	—	$	—	$	1,047,158


(1)	Includes management fees for providing management and administrative services to dialysis centers that are wholly-owned by third parties and legal entities in which the Company owns a noncontrolling equity investment.


~~(2)~~	Includes medical consulting service fees and management fees for providing management and administrative services to unconsolidated joint ventures and revenue related to the maintenance of existing physician networks.


~~(3)~~	~~U.S. dialysis and related lab services operating income includes the net gain on the settlement with the VA.~~